621 lines
426 KiB
Text
621 lines
426 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK561115">
|
|
<meta name="ncbi_domain" content="niceng140er10">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK561115/?report=reader">
|
|
<meta name="ncbi_pagename" content="Misoprostol after mifepristone for inducing medical abortion between 10+1 and 24+0 weeks’ gestation - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Misoprostol after mifepristone for inducing medical abortion between 10+1 and 24+0 weeks’ gestation - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="National Guideline Alliance (UK)">
|
|
<meta name="citation_title" content="Misoprostol after mifepristone for inducing medical abortion between 10+1 and 24+0 weeks’ gestation">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2019/09">
|
|
<meta name="citation_author" content="National Guideline Alliance (UK)">
|
|
<meta name="citation_pmid" content="32813465">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK561115/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Misoprostol after mifepristone for inducing medical abortion between 10+1 and 24+0 weeks’ gestation">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Contributor" content="National Guideline Alliance (UK)">
|
|
<meta name="DC.Date" content="2019/09">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK561115/">
|
|
<meta name="og:title" content="Misoprostol after mifepristone for inducing medical abortion between 10+1 and 24+0 weeks’ gestation">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK561115/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng140er10-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng140er10/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK561115/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E29367D73A53100000000005A0043.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK561115/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK561115/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK561115/&text=Misoprostol%20after%20mifepristone%20for%20inducing%20medical%20abortion%20between%2010%2B1%20and%2024%2B0%20weeks%02019%20gestation"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK561115/?report=classic">Switch to classic view</a><a href="/books/n/niceng140er10/pdf/">PDF (1.4M)</a><a href="/books/n/niceng140er10/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK561115%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E29367D73A53100000000005A0043.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng140er10-lrg.png" alt="Cover of Misoprostol after mifepristone for inducing medical abortion between 10+1 and 24+0 weeks’ gestation" /></a></div><div class="bkr_bib"><h1 id="_NBK561115_"><span itemprop="name">Misoprostol after mifepristone for inducing medical abortion between 10+1 and 24+0 weeks’ gestation</span></h1><div class="subtitle">Abortion care</div><p><b>Evidence review J</b></p><p><i>NICE Guideline, No. 140</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">National Guideline Alliance (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2019 Sep</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-3539-0</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2019.</div></div><div class="bkr_clear"></div></div><div id="ch10.s1"><h2 id="_ch10_s1_">Misoprostol after mifepristone for inducing medical abortion between 10<sup>+1</sup> and 24<sup>+0</sup> weeks’ gestation</h2><div id="ch10.s1.1"><h3>Review question</h3><p>What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</p><div id="ch10.s1.1.1"><h4>Introduction</h4><p>The aim of this review is to determine the optimal regimen and route of administration for misoprostol (after mifepristone) between 10<sup>+1</sup> and 24<sup>+0</sup> weeks’ gestation for medical abortion.</p><p>At the time of development, the title of this guideline was ‘Termination of pregnancy’ and this term was used throughout the guideline. In response to comments from stakeholders, the title was changed to ‘Abortion care’ and abortion has been used throughout. Therefore, both terms appear in this evidence report.</p></div><div id="ch10.s1.1.2"><h4>PICO table</h4><p>See <a class="figpopup" href="/books/NBK561115/table/ch10.tab1/?report=objectonly" target="object" rid-figpopup="figch10tab1" rid-ob="figobch10tab1">Table 1</a> for a summary of the population, intervention, comparison and outcome (PICO) characteristics of this review.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch10tab1"><a href="/books/NBK561115/table/ch10.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figch10tab1" rid-ob="figobch10tab1"><img class="small-thumb" src="/books/NBK561115/table/ch10.tab1/?report=thumb" src-large="/books/NBK561115/table/ch10.tab1/?report=previmg" alt="Table 1. Summary of the protocol (PICO table)." /></a><div class="icnblk_cntnt"><h4 id="ch10.tab1"><a href="/books/NBK561115/table/ch10.tab1/?report=objectonly" target="object" rid-ob="figobch10tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">Summary of the protocol (PICO table). </p></div></div></div><div id="ch10.s1.1.3"><h4>Clinical evidence</h4><div id="ch10.s1.1.3.1"><h5>Included studies</h5><p>Only studies conducted from 1985 onwards were considered for this review question, as mifepristone was made available in the UK in 1991 and evidence to support the use of mifepristone in practice was unlikely to be more than 5 years before its licensing in 1991.</p><p>Eleven randomised controlled trials (RCTs; number of participants, n=1,951) were included in the review (<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>; <a class="bibr" href="#ch10.s1.1.ref2" rid="ch10.s1.1.ref2">Brouns 2010</a>; <a class="bibr" href="#ch10.s1.1.ref3" rid="ch10.s1.1.ref3">Chai 2009</a>; <a class="bibr" href="#ch10.s1.1.ref4" rid="ch10.s1.1.ref4">Dickinson 2014</a>; <a class="bibr" href="#ch10.s1.1.ref5" rid="ch10.s1.1.ref5">El-Refaey 1995</a>; <a class="bibr" href="#ch10.s1.1.ref6" rid="ch10.s1.1.ref6">Hamoda 2005</a>; <a class="bibr" href="#ch10.s1.1.ref7" rid="ch10.s1.1.ref7">Ho 1997</a>; <a class="bibr" href="#ch10.s1.1.ref8" rid="ch10.s1.1.ref8">Hou 2010</a>; <a class="bibr" href="#ch10.s1.1.ref9" rid="ch10.s1.1.ref9">Mentula 2011</a>; <a class="bibr" href="#ch10.s1.1.ref10" rid="ch10.s1.1.ref10">Ngai 2000</a>; <a class="bibr" href="#ch10.s1.1.ref12" rid="ch10.s1.1.ref12">Tang 2005</a>).</p><p>Four RCTs (<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>; <a class="bibr" href="#ch10.s1.1.ref3" rid="ch10.s1.1.ref3">Chai 2009</a>; <a class="bibr" href="#ch10.s1.1.ref8" rid="ch10.s1.1.ref8">Hou 2010</a>; <a class="bibr" href="#ch10.s1.1.ref9" rid="ch10.s1.1.ref9">Mentula 2011</a>) compared mifepristone-misoprostol dosing intervals (simultaneous versus 24 hours, simultaneous versus 36 to 38 hours, 24 hours versus 48 hours); 6 RCTs (<a class="bibr" href="#ch10.s1.1.ref4" rid="ch10.s1.1.ref4">Dickinson 2014</a>; <a class="bibr" href="#ch10.s1.1.ref5" rid="ch10.s1.1.ref5">El-Rafaey 1995</a>; <a class="bibr" href="#ch10.s1.1.ref6" rid="ch10.s1.1.ref6">Hamoda 2005</a>; <a class="bibr" href="#ch10.s1.1.ref7" rid="ch10.s1.1.ref7">Ho 1997</a>; <a class="bibr" href="#ch10.s1.1.ref10" rid="ch10.s1.1.ref10">Ngai 2000</a>; <a class="bibr" href="#ch10.s1.1.ref12" rid="ch10.s1.1.ref12">Tang 2005</a>) compared 2 or more different misoprostol routes of administration (oral versus vaginal, sublingual versus vaginal, oral versus sublingual versus vaginal) and 1 RCT (<a class="bibr" href="#ch10.s1.1.ref2" rid="ch10.s1.1.ref2">Brouns 2010</a>) compared 2 different doses of misoprostol (400 micrograms versus 200 micrograms).</p><p>There was no subgroup data available based on medical conditions, gestational age, parity and history of previous caesarean section.</p><p>The included studies are summarised in <a class="figpopup" href="/books/NBK561115/table/ch10.tab2/?report=objectonly" target="object" rid-figpopup="figch10tab2" rid-ob="figobch10tab2">Table 2</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch10tab2"><a href="/books/NBK561115/table/ch10.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figch10tab2" rid-ob="figobch10tab2"><img class="small-thumb" src="/books/NBK561115/table/ch10.tab2/?report=thumb" src-large="/books/NBK561115/table/ch10.tab2/?report=previmg" alt="Table 2. Summary of included studies." /></a><div class="icnblk_cntnt"><h4 id="ch10.tab2"><a href="/books/NBK561115/table/ch10.tab2/?report=objectonly" target="object" rid-ob="figobch10tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of included studies. </p></div></div><p>See the literature search strategy in <a href="#ch10.appb">appendix B</a> and study selection flow chart in <a href="#ch10.appc">appendix C</a>.</p></div><div id="ch10.s1.1.3.2"><h5>Excluded studies</h5><p>Studies not included in this review with reasons for their exclusions are provided in <a href="#ch10.appk">appendix K</a>.</p></div></div><div id="ch10.s1.1.4"><h4>Summary of clinical studies included in the evidence review</h4><p>A summary of the studies that were included in this review are presented in <a class="figpopup" href="/books/NBK561115/table/ch10.tab2/?report=objectonly" target="object" rid-figpopup="figch10tab2" rid-ob="figobch10tab2">Table 2</a>.</p><p>See the full evidence tables in <a href="#ch10.appd">appendix D</a> and the forest plots in <a href="#ch10.appe">appendix E</a>.</p></div><div id="ch10.s1.1.5"><h4>Quality assessment of clinical studies included in the evidence review</h4><p>See the clinical evidence profiles in <a href="#ch10.appf">appendix F</a>.</p></div><div id="ch10.s1.1.6"><h4>Economic evidence</h4><div id="ch10.s1.1.6.1"><h5>Included studies</h5><p>A systematic review of the economic literature was conducted but no economic studies were identified which were applicable to this review question.</p><p>A single economic search was undertaken for all topics included in the scope of this guideline. See <a href="/books/NBK561115/bin/bm2.pdf">supplementary material 2</a> for details.</p></div><div id="ch10.s1.1.6.2"><h5>Excluded studies</h5><p>No full-text copies of articles were requested for this review and so there is no excluded studies list.</p></div></div><div id="ch10.s1.1.7"><h4>Economic model</h4><p>No economic modelling was undertaken for this review because the committee agreed that other topics were higher priorities for economic evaluation.</p></div><div id="ch10.s1.1.8"><h4>Evidence statements</h4></div><div id="ch10.s1.1.9"><h4>Comparison 1. 200 mcg versus 400 mcg vaginal misoprostol (at 4 hour intervals) 36 to 48 hours after oral mifepristone 200 mg</h4><div id="ch10.s1.1.9.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.9.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed that the time to expulsion was statistically<sup><a href="#ch10.fn1">a</a></sup>
|
|
significantly longer in the 200 mcg vaginal misoprostol group (median [range]=9.2 [7.1 to 11.3] hours) compared with the 400 mcg vaginal misoprostol group (median [range]=8.0 [7.1 to 8.9] hours; 1 RCT, n=176; low quality)</p></div><div id="ch10.s1.1.9.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in complete abortion rate without the need for surgical intervention (at 48 hours) between the 200 mcg vaginal misoprostol group and the 400 mcg vaginal misoprostol group (1 RCT, n=176; RR=0.9 [95% CI 0.74, 1.10]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.9.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the incomplete abortion rate with the need for surgical intervention between the 200 mcg vaginal misoprostol group and the 400 mcg vaginal misoprostol group (1 RCT, n=176; RR=1.26 [95% CI 0.80, 1.99]; low quality); however, there was uncertainty around the estimate.</p></div></div><div id="ch10.s1.1.9.2"><h5>Important outcomes</h5><div id="ch10.s1.1.9.2.1"><h5>Haemorrhage requiring transfusion or >500 ml of blood loss</h5><p>RCT evidence did not detect a clinically important difference in the rate of haemorrhage requiring transfusion or >500 ml of blood loss between the 200 mcg vaginal misoprostol group and the given 400 mcg vaginal misoprostol group (1 RCT, n=176; RR=1.4 [95% CI 0.32, 6.05]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.9.2.2"><h5>Vomiting</h5><p>RCT evidence did not detect a clinically important difference in the rate of vomiting between the 200 mcg vaginal misoprostol group and the 400 mcg vaginal misoprostol group (1 RCT, n=176; RR=0.76 [95% CI 0.51, 1.14]; moderate quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.9.2.3"><h5>Patient satisfaction</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.9.2.4"><h5>Diarrhoea</h5><p>RCT evidence did not detect a clinically important difference in the rate of diarrhoea between the 200 mcg vaginal misoprostol group and the 400 mcg vaginal misoprostol group (1 RCT, n=176; RR=0.52 [95% CI 0.19, 1.47]; low quality); however, there was uncertainty around the estimate.</p></div></div></div><div id="ch10.s1.1.10"><h4>Comparison 2. Vaginal versus oral misoprostol (400 mcg, at 3 hour intervals up to 4 doses following a loading dose of vaginal misoprostol 600 mcg) 36 to 48 hours after oral mifepristone 600 mg</h4><div id="ch10.s1.1.10.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.10.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed there was no clinically important difference in the time to expulsion between the 400 mcg vaginal misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=69; MD= −0.7 [95% CI −2.03, 0.63]; high quality)</p></div><div id="ch10.s1.1.10.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>RCT evidence did not a detect a clinically important difference in the complete abortion rate without the need for surgical intervention (at 48 hours) between the 400 mcg vaginal misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=69; RR=1.0 [95% CI 0.92, 1.09]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.10.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the incomplete abortion rate with the need for surgical intervention between the 400 mcg vaginal misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=69; RR=3.09 [95% CI 0.13, 73.21]; low quality); however, there was uncertainty around the estimate.</p></div></div><div id="ch10.s1.1.10.2"><h5>Important outcomes</h5><div id="ch10.s1.1.10.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>RCT evidence reported no events of haemorrhage requiring transfusion or >500 ml of blood loss in either the 400 mcg vaginal misoprostol group or the 400 mcg oral misoprostol group; therefore differences between groups could not be estimated (1 RCT, n=69;low quality).</p></div><div id="ch10.s1.1.10.2.2"><h5>Vomiting</h5><p>RCT evidence did not detect a clinically important difference in the rate of vomiting between the 400 mcg vaginal misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=69; RR=0.93 [95% CI 0.63, 1.37]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.10.2.3"><h5>Patient satisfaction</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.10.2.4"><h5>Diarrhoea</h5><p>RCT evidence did not detect a clinically important difference in the rate of diarrhoea between the 400 mcg vaginal misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=69; RR=0.81 [95% CI 0.40, 1.62]; low quality); however, there was uncertainty around the estimate.</p></div></div></div><div id="ch10.s1.1.11"><h4>Comparison 3. Vaginal versus oral misoprostol (400 mcg; at 4 hour intervals for vaginal misoprostol and 3 hour intervals for oral misoprostol, up to 5 doses following a loading dose of vaginal misoprostol 800 mcg) 24 to 48 hours after oral mifepristone 200 mg</h4><div id="ch10.s1.1.11.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.11.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed that the time to expulsion was statistically<sup><a href="#ch10.fn2">b</a></sup> significantly shorter in the 400 mcg vaginal misoprostol group (median [range]=7.4 [6.5 to 8.2] hours) compared with the 400 mcg oral misoprostol group (median [range]=9.5 (8.5 to 11.4) hours; 1 RCT, n=200; moderate quality).</p></div><div id="ch10.s1.1.11.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.11.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>No evidence was identified to inform this outcome.</p></div></div><div id="ch10.s1.1.11.2"><h5>Important outcomes</h5><div id="ch10.s1.1.11.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>RCT evidence did not detect a clinically important difference in the rate of haemorrhage requiring transfusion or >500 ml of blood loss between the 400 mcg vaginal misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=200; RR=0.50 [95% CI 0.05, 5.43]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.11.2.2"><h5>Vomiting</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.11.2.3"><h5>Patient satisfaction (opinion of procedure score)</h5><p>RCT evidence did not detect a clinically important difference in the opinion of procedure (with lower scores indicating “better than expected” and higher scores indicating “worse than expected”) patient satisfaction score between the 400 mcg vaginal misoprostol group (median [range]=50 [26 to 50]) and the 400 mcg oral misoprostol group (median [range]=50 [20 to 50]; 1 RCT, n=200; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.11.2.4"><h5>Diarrhoea</h5><p>No evidence was identified to inform this outcome.</p></div></div></div><div id="ch10.s1.1.12"><h4>Comparison 4. Vaginal versus oral misoprostol (200 mcg; at 3 hour intervals, up to 5 doses) ± placebo 36 to 48 hours after 200 mg oral mifepristone</h4><div id="ch10.s1.1.12.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.12.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed a shorter clinically important difference in the time to expulsion in the 200 mcg vaginal misoprostol group compared with the 200 mcg oral misoprostol group (1 RCT, n=98; MD=-13 [95% CI −23.23, −2.77]; low quality).</p></div><div id="ch10.s1.1.12.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the complete abortion rate without the need for surgical intervention (at 48 hours) between the 200 mcg vaginal misoprostol group and the 200 mcg oral misoprostol group (1 RCT, n=98; RR=1.24 [95% CI 0.93, 1.65]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.12.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>No evidence was identified to inform this outcome.</p></div></div><div id="ch10.s1.1.12.2"><h5>Important outcomes</h5><div id="ch10.s1.1.12.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.12.2.2"><h5>Vomiting</h5><p>RCT evidence did not detect a clinically important difference in the rate of vomiting between the 200 mcg vaginal misoprostol group and the 200 mcg oral misoprostol group (1 RCT, n=98; RR=1.40 [95% CI 0.69, 2.84]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.12.2.3"><h5>Patient satisfaction</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.12.2.4"><h5>Diarrhoea</h5><p>RCT evidence did not detect a clinically important difference in the rate of diarrhoea between the 200 mcg vaginal misoprostol group and the 200 mcg oral misoprostol group (1 RCT, n=98; RR=0.56 [95% CI 0.28, 1.15]; moderate quality); however, there was uncertainty around the estimate.</p></div></div></div><div id="ch10.s1.1.13"><h4>Comparison 5. Oral versus vaginal misoprostol (400 mcg at 3 hour intervals, up to 5 doses) ± placebo 36 to 48 hours after oral mifepristone 200 mg</h4><div id="ch10.s1.1.13.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.13.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed there was no clinically important difference in the time to expulsion between the 400 mcg oral misoprostol group and the 400 mcg vaginal misoprostol group (1 RCT, n=139; MD=-1.3 [95% CI −8.7, 11.33]; moderate quality).</p></div><div id="ch10.s1.1.13.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the complete abortion rate without the need for surgical intervention (at 48 hours) between the 400 mcg oral misoprostol group and the 400 mcg vaginal misoprostol group (1 RCT, n=139; RR=0.97 [95% CI 0.83, 1.13]; very low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.13.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>RCT evidence reported no events of incomplete abortion with the need for surgical intervention in either the 400 mcg oral misoprostol group or the 400 mcg vaginal misoprostol group; therefore differences between groups could not be estimated (1 RCT, n=139; very low quality).</p></div></div><div id="ch10.s1.1.13.2"><h5>Important outcomes</h5><div id="ch10.s1.1.13.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.13.2.2"><h5>Vomiting</h5><p>RCT evidence did not detect a clinically important difference in the rate of vomiting between the 400 mcg oral misoprostol group and the 400 mcg vaginal misoprostol group (1 RCT, n=139; RR=1.05 [95% CI 0.72, 1.54]; very low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.13.2.3"><h5>Patient satisfaction</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.13.2.4"><h5>Diarrhoea</h5><p>RCT evidence showed a higher clinically important difference in the rate of diarrhoea in the 400 mcg oral misoprostol group compared to the 400 mcg vaginal misoprostol group (1 RCT, n=139; RR=1.73 [95% CI 1.03, 2.89]; low quality).</p></div></div></div><div id="ch10.s1.1.14"><h4>Comparison 6. Sublingual versus oral misoprostol (400 mcg; at 3 hour intervals, up to 5 doses following a loading dose of vaginal misoprostol 800 mcg) 24 to 48 hours after oral mifepristone 200 mg</h4><div id="ch10.s1.1.14.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.14.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed that the time to expulsion was statistically<sup><a href="#ch10.fn3">c</a></sup> significantly shorter in the 400 mcg sublingual misoprostol group (median [range]=7.8 [7.0 to 9.2] hours) compared with the 400 mcg oral misoprostol group (median [range]=9.5 [8.5 to 11.4] hours; 1 RCT, n=202; moderate quality).</p></div><div id="ch10.s1.1.14.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.14.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>No evidence was identified to inform this outcome.</p></div></div><div id="ch10.s1.1.14.2"><h5>Important outcomes</h5><div id="ch10.s1.1.14.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>RCT evidence did not detect a clinically important difference in the rate of haemorrhage requiring transfusion or >500 ml of blood loss between the 400 mcg sublingual misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=202; RR=0.98 [95% CI 0.14, 6.83]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.14.2.2"><h5>Vomiting</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.14.2.3"><h5>Patient satisfaction (opinion of procedure score)</h5><p>RCT evidence did not detect a clinically important difference in the opinion of procedure (with lower scores indicating “better than expected” and higher scores indicating “worse than expected”) patient satisfaction score between the 400 mcg sublingual misoprostol group (median [range]=50 [19 to 50]) and the 400 mcg oral misoprostol group (median [range]=50 [20 to 50]; 1 RCT, n=202; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.14.2.4"><h5>Diarrhoea</h5><p>No evidence was identified to inform this outcome.</p></div></div></div><div id="ch10.s1.1.15"><h4>Comparison 7. Sublingual versus oral misoprostol (400 mcg, at 3 hour intervals up to 5 doses) 36 to 48 hours after oral mifepristone 200 mg</h4><div id="ch10.s1.1.15.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.15.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed that the time to expulsion was statistically<sup><a href="#ch10.fn4">d</a></sup> significantly shorter in the 400 mcg sublingual misoprostol group (median [range]=5.5 [1.4 to 43.2] hours) compared with the 400 mcg oral misoprostol group (median [range]=7.5 [2.4 to 38.8] hours; 1 RCT, n=118; low quality).</p></div><div id="ch10.s1.1.15.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the complete abortion rate without the need for surgical intervention (at 48 hours) between the 400 mcg sublingual misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=118; RR=1.07 [95% CI 0.99-1.17]; moderate quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.15.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>RCT evidence showed did not detect a clinically important difference in the incomplete abortion rate with the need for surgical intervention between the 400 mcg sublingual misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=118; RR=1.48 [95% CI 0.60, 3.62]; low quality); however, there was uncertainty around the estimate.</p></div></div><div id="ch10.s1.1.15.2"><h5>Important outcomes</h5><div id="ch10.s1.1.15.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.15.2.2"><h5>Vomiting</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.15.2.3"><h5>Patient satisfaction</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.15.2.4"><h5>Diarrhoea</h5><p>RCT evidence showed did not detect a clinically important difference in the rate of diarrhoea between the 400 mcg sublingual misoprostol group and the 400 mcg oral misoprostol group (1 RCT, n=118; RR=0.64 [95% CI 0.29, 1.42]; low quality); however, there was uncertainty around the estimate.</p></div></div></div><div id="ch10.s1.1.16"><h4>Comparison 8. Sublingual (600 mcg; followed by 400 mcg at 3 hour intervals up to 5 doses) versus vaginal (800 mcg; followed by 400 mcg at 3 hour intervals up to 5 doses) misoprostol, 36 to 48 hours after oral mifepristone 200 mg</h4><div id="ch10.s1.1.16.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.16.1.1"><h5>Time to expulsion</h5><p>RCT evidence did not detect a clinically important difference in the time to expulsion between the 600 mcg sublingual misoprostol group (median [range]=5.27 [0.55 to 29.35] hours) and the 800 mcg vaginal misoprostol group (median [range]=5.40 [2.10 to 13.00] hours; 1 RCT, n=76; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.16.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.16.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the rate of incomplete abortion with the need for surgical intervention between the 600 mcg sublingual misoprostol group and the 800 mcg vaginal misoprostol group (1 RCT, n=76; RR=3.33 [95% CI 0.36, 30.63]; low quality); however, there was uncertainty around the estimate.</p></div></div><div id="ch10.s1.1.16.2"><h5>Important outcomes</h5><div id="ch10.s1.1.16.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.16.2.2"><h5>Vomiting</h5><p>RCT evidence did not detect a clinically important difference in the rate of vomiting between the 600 mcg sublingual misoprostol group and the 800 mcg vaginal misoprostol group (1 RCT, n=76; RR=1.11 [95% CI 0.80, 1.54]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.16.2.3"><h5>Patient satisfaction (satisfied with the route of administration)</h5><p>RCT evidence did not detect a clinically important difference in the rate of women who were “satisfied” with the route of administration of misoprostol between the 600 mcg sublingual misoprostol group and the 800 mcg vaginal misoprostol group (1 RCT, n=76; RR=1.07 [95% CI 0.76, 1.49]; very low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.16.2.4"><h5>Diarrhoea</h5><p>RCT evidence did not detect a clinically important difference in the rate of diarrhoea between the 600 mcg sublingual misoprostol group and the 800 mcg vaginal misoprostol group (1 RCT, n=76; RR=1.01 [95% CI 0.66, 1.54]; low quality); however, there was uncertainty around the estimate.</p></div></div></div><div id="ch10.s1.1.17"><h4>Comparison 9. Oral misoprostol (400 mcg; every 6 hours, up to 2 doses) 1 versus 2 days after oral mifepristone 200 mg + 600 mcg vaginal misoprostol</h4><div id="ch10.s1.1.17.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.17.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed there was no clinically important difference in the time to expulsion between the oral misoprostol 1 day after oral mifepristone group and the oral misoprostol 2 days after oral mifepristone group (1 RCT, n=100; MD=0.20 [95% CI −1.25,1.65]; low quality).</p></div><div id="ch10.s1.1.17.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>RCT evidence showed a lower clinically important difference in the rate of complete abortion without the need for surgical intervention (at 24 hours) in the oral misoprostol 1 day after oral mifepristone group compared with the oral misoprostol 2 days after oral mifepristone group (1 RCT, n=100; RR=0.68 [95% CI 0.47, 0.97]; low quality).</p></div><div id="ch10.s1.1.17.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the rate of incomplete abortion with the need for surgical intervention between the oral misoprostol 1 day after oral mifepristone group and the oral misoprostol 2 days after oral mifepristone group (1 RCT, n=100; RR=3 [95% CI 0.13, 71.92]; very low quality); however, there was uncertainty around the estimate..</p></div></div><div id="ch10.s1.1.17.2"><h5>Important outcomes</h5><div id="ch10.s1.1.17.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.17.2.2"><h5>Vomiting</h5><p>RCT evidence showed no clinically important difference in the rate of vomiting between the oral misoprostol 1 day after oral mifepristone group and the oral misoprostol 2 days after oral mifepristone group (1 RCT, n=100; RR=0.93 [95% CI 0.51, 1.72]; very low quality).</p></div><div id="ch10.s1.1.17.2.3"><h5>Patient satisfaction</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.17.2.4"><h5>Diarrhoea</h5><p>RCT evidence showed no clinically important difference in the rate of diarrhoea between the oral misoprostol 1 day after oral mifepristone group and the oral misoprostol 2 days after oral mifepristone group (1 RCT, n=100; RR=2.25 [95% CI 0.74, 6.83]; very low quality).</p></div></div></div><div id="ch10.s1.1.18"><h4>Comparison 10. Vaginal misoprostol (400 mcg; at 3 hour intervals, up to 5 doses per 24 hours) 1 versus 2 days after oral mifepristone 200 mg</h4><div id="ch10.s1.1.18.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.18.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed that the time to expulsion was statistically<sup><a href="#ch10.fn5">e</a></sup> significantly longer in the 400 mcg vaginal misoprostol 1 day after oral mifepristone group (median [range]=8.5 [6.3 to 12.3)] hours) compared with the 400 mcg vaginal misoprostol 2 days after oral mifepristone group (median [range]=7.2 [5.8 to 9.2] hours; 1 RCT, n=227; moderate quality).</p></div><div id="ch10.s1.1.18.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.18.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the rate of incomplete abortion with the need for surgical intervention between the 400 mcg vaginal misoprostol 1 day after oral mifepristone group and the 400 mcg vaginal misoprostol 2 days after oral mifepristone group (1 RCT, n=227; RR=0.69 [95% CI 0.46, 1.03]; moderate quality); however, there was uncertainty around the estimate.</p></div></div><div id="ch10.s1.1.18.2"><h5>Important outcomes</h5><div id="ch10.s1.1.18.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>RCT evidence did not detect a clinically important difference in the rate of haemorrhage requiring transfusion or >500 ml blood loss between the 400 mcg vaginal misoprostol 1 day after oral mifepristone group and the 400 mcg vaginal misoprostol 2 days after oral mifepristone group (1 RCT, n=227; RR=1.11 [95% CI 0.42, 2.97]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.18.2.2"><h5>Vomiting</h5><p>RCT evidence did not detect a clinically important difference in the rate of vomiting (need for anti-emetic drugs) between the 400 mcg vaginal misoprostol 1 day after oral mifepristone group and the 400 mcg vaginal misoprostol 2 days after oral mifepristone group (1 RCT, n=227; RR=1.22 [95% CI 0.76, 1.95]; very low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.18.2.3"><h5>Patient satisfaction</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.18.2.4"><h5>Diarrhoea</h5><p>No evidence was identified to inform this outcome.</p></div></div></div><div id="ch10.s1.1.19"><h4>Comparison 11. Vaginal misoprostol (600 mcg; followed by 400 mcg at 3 hour intervals, up to 4 doses) simultaneous with mifepristone 200 mg versus 36 to 38 hours after 200 mg oral mifepristone</h4><div id="ch10.s1.1.19.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.19.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed that the time to expulsion was statistically<sup><a href="#ch10.fn6">f</a></sup> significantly longer in the 600 mcg vaginal misoprostol simultaneously with oral mifepristone group (median [range]=10.0 [3.5 to 126] hours) compared with the 600 mcg vaginal misoprostol 36 to 38 hours after oral mifepristone group (median [range]=4.9 [1.8 to 13.8] hours; 1 RCT, n=141; low quality).</p></div><div id="ch10.s1.1.19.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the rate of complete abortion without the need for surgical intervention between the 600 mcg vaginal misoprostol simultaneously with oral mifepristone group and the 600 mcg vaginal misoprostol 36 to 38 hours after oral mifepristone group (1 RCT, n=141; RR=0.99 [95% CI 0.95, 1.03]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.19.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the rate of incomplete abortion with the need for surgical intervention between the 600 mcg vaginal misoprostol simultaneously with oral mifepristone group and the 600 mcg vaginal misoprostol 36 to 38 hours after oral mifepristone group (1 RCT, n=141; RR=4.93 [95% CI 0.59, 41.13]; low quality); however, there was uncertainty around the estimate.</p></div></div><div id="ch10.s1.1.19.2"><h5>Important outcomes</h5><div id="ch10.s1.1.19.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>RCT evidence reported no events of haemorrhage requiring transfusion or >500ml of blood loss in either the 600 mcg vaginal misoprostol simultaneously with oral mifepristone group or the 600 mcg vaginal misoprostol 36 to 38 hours after oral mifepristone group; therefore differences between groups could not be estimated (1 RCT, n=141;; low quality).</p></div><div id="ch10.s1.1.19.2.2"><h5>Vomiting</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.19.2.3"><h5>Patient satisfaction</h5><p>No evidence was identified to inform this outcome.</p></div><div id="ch10.s1.1.19.2.4"><h5>Diarrhoea</h5><p>RCT evidence did not detect a clinically important difference in the rate of diarrhoea (> 3 episodes) between the 600 mcg vaginal misoprostol simultaneously with oral mifepristone group and the 600 mcg vaginal misoprostol 36 to 38 hours after oral mifepristone group (1 RCT, n=141; RR=1.77 [95% CI 0.88, 3.57]; moderate quality); however, there was uncertainty around the estimate..</p></div></div></div><div id="ch10.s1.1.20"><h4>Comparison 12. Buccal misoprostol 400 mcg (at 3 hour intervals) ± placebo simultaneous with mifepristone 200 mg versus 1 day following oral mifepristone 200 mg</h4><div id="ch10.s1.1.20.1"><h5>Critical outcomes</h5><div id="ch10.s1.1.20.1.1"><h5>Time to expulsion</h5><p>RCT evidence showed that the time to expulsion was statistically<sup><a href="#ch10.fn7">g</a></sup> significantly longer in the buccal misoprostol simultaneously with oral mifepristone group (median [range]=13.0 [4.9 to 47.8] hours) compared with the 400 mcg buccal misoprostol 1 day after oral mifepristone group (median [range]=7.7 [2.1 to 40.3] hours; 1 RCT, n=505; moderate quality).</p></div><div id="ch10.s1.1.20.1.2"><h5>Complete abortion without the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the rate of complete abortion without the need for surgical intervention at 48 hours between the 400 mcg buccal misoprostol simultaneously with oral mifepristone group and the 400 mcg buccal misoprostol 1 day after oral mifepristone group (1 RCT, n=505; RR=0.99 [95% CI 0.95, 1.02]; low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.20.1.3"><h5>Incomplete abortion with the need for surgical intervention</h5><p>RCT evidence did not detect a clinically important difference in the rate of incomplete abortion with the need for surgical intervention between the 400 mcg buccal misoprostol simultaneously with oral mifepristone group and the 400 mcg buccal misoprostol 1 day after oral mifepristone group (1 RCT, n=505; RR=1.98 [95% CI 0.18, 21.66]; very low quality); however, there was uncertainty around the estimate.</p></div></div><div id="ch10.s1.1.20.2"><h5>Important outcomes</h5><div id="ch10.s1.1.20.2.1"><h5>Haemorrhage requiring transfusion or >500ml of blood loss</h5><p>RCT evidence did not detect a clinically important difference in the rate of haemorrhage requiring transfusion or >500ml of blood loss between the 400 mcg buccal misoprostol simultaneously with oral mifepristone group and the 400 mcg buccal misoprostol 1 day after oral mifepristone group (1 RCT, n=505; RR=2.96 [95% CI 0.12, 72.43]; very low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.20.2.2"><h5>Vomiting</h5><p>RCT evidence did not detect a clinically important difference in the rate of vomiting between the 400 mcg buccal misoprostol simultaneously with oral mifepristone group and the 400 mcg buccal misoprostol 1 day after oral mifepristone group (1 RCT, n=505; RR=1.09 [95% CI 0.8, 1.49]; very low quality); however, there was uncertainty around the estimate.</p></div><div id="ch10.s1.1.20.2.3"><h5>Patient satisfaction (satisfied or very satisfied)</h5><p>RCT evidence showed there was no clinically important difference in the rate of patient satisfaction (satisfied or very satisfied) between the 400 mcg buccal misoprostol simultaneously with oral mifepristone group and the 400 mcg buccal misoprostol 1 day after oral mifepristone group (1 RCT, n=505; RR=1 [95% CI 0.98, 1.02]; moderate quality).</p></div><div id="ch10.s1.1.20.2.4"><h5>Diarrhoea</h5><p>RCT evidence showed there was a higher clinically important difference in the rate of diarrhoea in the 400 mcg buccal misoprostol simultaneously with oral mifepristone group compared to the 400 mcg buccal misoprostol 1 day after oral mifepristone group (1 RCT, n=505; RR=1.63 [95% CI 1.32, 2.01]; moderate quality).</p></div></div></div><div id="ch10.s1.1.21"><h4>The committee’s discussion of the evidence</h4><div id="ch10.s1.1.21.1"><h5>Interpreting the evidence</h5><div id="ch10.s1.1.21.1.1"><h5>The outcomes that matter most</h5><p>The main aim of this review was to determine the optimal dose regimen and route of administration of misoprostol, following mifepristone for the medical abortion of pregnancy between 10<sup>+1</sup> and 24<sup>+0</sup> weeks. The committee agreed that, the time to expulsion should be prioritised as a critical outcome as it varies with the dose regimen, the route of administration and the dosing interval of misoprostol and was critical for decision making given its implications for the woman and the health care resources. Complete abortion without the need for surgical intervention and incomplete abortion with the need for surgical intervention were selected as critical outcomes as they may have implications for the woman in terms of having to undergo surgical intervention and also impact resources. Haemorrhage requiring transfusion of greater than 500 ml of blood loss was considered an important outcome for decision making, because of the seriousness of the outcome. Patient satisfaction was considered as an important outcome as abortion is an area where women are known to have strong preferences. Vomiting and diarrhoea were included as important outcomes to allow for a balance of the benefits and harms as the likelihood of these occurring differs with the dose regimens, routes of administration and dosing intervals of misoprostol and they are likely to impact patient satisfaction.</p></div><div id="ch10.s1.1.21.1.2"><h5>The quality of the evidence</h5><p>The evidence in the pairwise comparisons was assessed using the GRADE methodology. Evidence for time to expulsion ranged from low to high quality; the main reason evidence was downgraded was for imprecision caused by few events of interest but there was also risk of bias due to unclear randomization and unclear allocation concealment methods. Evidence for complete abortion without the need for surgical intervention ranged from very low to moderate quality; the main reason evidence was downgraded was due to imprecision caused by 95% confidence intervals crossing minimally important difference (MID) values and risk of bias caused by inadequate information regarding randomization and allocation concealment for studies comparing misoprostol regimens. The evidence for rate of incomplete abortion with the need for surgical intervention was very low to moderate quality. As with complete abortion rate, the reasons to downgrade the evidence was imprecision and risk of bias in studies reporting this outcome. The evidence for the outcome, haemorrhage requiring transfusion or >500 ml of blood loss was very low to low quality. The reasons for downgrading of evidence were imprecision caused by a small number or no events of interest and risk of bias in the included studies due to unclear randomization methods. Evidence for vomiting and diarrhoea ranged from very low to moderate quality; the most common reasons for downgrading evidence was imprecision due to wide confidence intervals and risk of bias due to attrition and insufficient information about randomization and allocation concealment methods. Evidence for patient satisfaction was of very low to moderate quality, mainly due to risk of bias because of lack of blinding and imprecision due to small number of events of interest.</p></div><div id="ch10.s1.1.21.1.3"><h5>Benefits and harms</h5><p>There was evidence from 11 randomised controlled trials regarding the comparison of dose regimens for the medical abortion between 10<sup>+1</sup> and 24<sup>+0</sup> weeks of gestation. The randomised trials compared dose regimens with different misoprostol doses, misoprostol routes and mifepristone-misoprostol intervals. Despite the fact that there were more than 1 study reporting the comparison between 2 routes of administration or mifepristone-misoprostol intervals, pooling of results of the trials was not possible due to the difference in drug regimens, including the loading dose and intervals between two doses. Hence, pairwise comparison was conducted for all comparisons. The committee discussed that most studies included a loading dose of vaginal misoprostol in their regimen. The committee noted the biological plausibility of administering a loading dose in this gestation age group to harness the prostaglandin sensitivity. There was some evidence regarding the administration of misoprostol by oral, sublingual and vaginal routes following a loading dose of 800 mcg vaginal misoprostol. There was also evidence from dose regimens using buccal route of administration. The committee noted that presently, a loading dose of 800 mcg vaginal misoprostol is administered for abortion before 10 weeks, and discussed that using the same loading dose after 10 weeks would keep the loading dose regimen standardised and it would be operationally easier for the staff to follow the same regimen up to 24 weeks. Hence, the committee made the recommendation regarding the misoprostol loading dose regimen of 800 mcg vaginal misoprostol followed by 400 mcg doses of misoprostol every 3 hours until expulsion (vaginal, sublingual or buccal route). The committee recognised that, for some women vaginal route may not be the preferred route of administration. There was some evidence that there was no difference in time to expulsion, the rate of complete abortion and gastrointestinal side effects between sublingual and vaginal routes of misoprostol administration. Hence, the committee discussed that if vaginal route was not preferred by the woman, then a loading dose of misoprostol could be administered sublingually. The sublingual loading dose was taken from this study comparing regimens with loading dose of 800 mcg vaginal misoprostol and 600 mcg sublingual misoprostol.</p><p>Although only 1 trial directly compared the follow up dose of 400 mcg of misoprostol administered through oral, sublingual and vaginal routes but the vast majority of included studies used 400 mcg doses of misoprostol. Considering the weight of the evidence and the evidence from 1 trial showing that a direct comparison of 200 mcg with 400 mcg showed a longer time to expulsion with 200 mcg, the committee agreed that following the loading dose, 400 mcg of misoprostol should be offered every 3 hours until expulsion.</p><p>There was evidence that the time to expulsion was statistically significantly longer with the simultaneous administration of misoprostol with mifepristone or a shorter mifepristone-misoprostol interval. It was unclear whether there was a clinically important difference in the outcome between the treatment groups because the way it was reported in 3 studies (as medians) precluded the possibility of calculation of minimally important differences. The committee discussed that a shorter time to expulsion following larger interval between mifepristone and misoprostol administration was biologically plausible between 10<sup>+1</sup> and 24<sup>+0</sup> weeks’ gestation, as a larger fetus may benefit from a greater cervical dilation effect of mifepristone and sensitisation of the uterus. Time to expulsion was 1 of the critical outcomes for this review and hence, the committee agreed that misoprostol should be administered 36 to 48 hours after the administration of mifepristone for abortion between 10<sup>+1</sup> and 24<sup>+0</sup> weeks’ gestation. The interval of 36 to 48 hours was chosen as there was evidence of effectiveness for dose regimens with this interval for vaginal and sublingual misoprostol with the same loading and follow-up doses, as included in the recommendation. It was also the most commonly used dosing interval in the included trials, reported in 4 out of 11 included trials.</p><p>The committee recognised that, sometimes it may not be possible to have the dosing interval of 36 to 48 hours between mifepristone and misoprostol as the women may not prefer a long interval between the 2 drugs, either due to service provision or other factors making it less convenient for her. The committee agreed that convenience of women should be an important consideration, and hence, the committee agreed that, in such situations, a shorter mifepristone-misoprostol interval should be considered. However, the committee noted that, in such circumstances, the woman should be informed regarding the longer time to induction associated with a shorter duration between mifepristone and misoprostol administration.</p><p>As there was sufficient evidence to inform the recommendations, the committee decided to prioritise other areas addressed by the guideline for future research and therefore made no research recommendations regarding the optimal regimen and route of administration of misoprostol after mifepristone for inducing medical abortion between 10<sup>+1</sup> and 24<sup>+0</sup> weeks.</p></div></div><div id="ch10.s1.1.21.2"><h5>Cost effectiveness and resource use</h5><p>A systematic review of the economic literature was conducted but no relevant studies were identified which were applicable to this review question.</p><p>The committee considered that there was unlikely to be a significant resource impact from the recommendations made. The use of oral misoprostol, which has a longer time to expulsion and higher number of adverse effects than vaginal or sublingual route, is likely to reduce with the recommendations. Any net effect of this change is likely to be cost saving with reduction in the hospitalisation time.</p></div><div id="ch10.s1.1.21.3"><h5>Other consideration</h5><p>There was some evidence that vaginal and sublingual routes of administration were associated with a shorter time to expulsion and vaginal route was associated with fewer gastrointestinal side effects, when compared to oral route of administration of misoprostol. Hence, the committee did not make a recommendation about administering misoprostol by oral route. However, the committee discussed that practitioners could consider administering misoprostol orally for repeat doses if other routes of administration are not acceptable to the woman or not appropriate. The committee also noted that, when doing so, it is important that women are advised that oral administration of misoprostol is associated with a longer induction to expulsion interval than administration by other routes.</p><p>The committee were aware of guidelines from the Royal College of Obstetricians and Gynaecologists that recommend feticide is used for abortion after 21<sup>+6</sup> weeks’ gestation (<a class="bibr" href="#ch10.s1.1.ref11" rid="ch10.s1.1.ref11">RCOG 2011</a>).</p><p>The evidence considered for this review question covered the gestational age range between 10<sup>+1</sup> and 24<sup>+0</sup> weeks’ gestation. However, recommendations were made for women between 10<sup>+1</sup> and 23<sup>+6</sup> weeks’ gestation to be consistent with the requirements of the 1967 Abortion Act.</p></div></div><div id="ch10.rl.r1"><h4>References</h4><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref1"><p id="p-291">
|
|
<strong>Abbas 2016</strong>
|
|
</p>Abbas, D. F., Blum, J., Ngoc, N. T. N., Nga, N. T. B., Chi, H. T. K., Martin, R., Winikoff, B.(2016). Simultaneous Administration Compared with a 24-Hour Mifepristone-Misoprostol Interval in Second-Trimester Abortion, Obstetrics and Gynecology, 128, 1077–1083. [<a href="https://pubmed.ncbi.nlm.nih.gov/27741182" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27741182</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref2"><p id="p-292">
|
|
<strong>Brouns 2010</strong>
|
|
</p>Brouns, J. F. G. M., Van Wely, M., Burger, M. P. M., Van Wijngaarden, W. J. (2010). Comparison of two dose regimens of misoprostol for second-trimester pregnancy termination, Contraception, 82, 266–275. [<a href="https://pubmed.ncbi.nlm.nih.gov/20705156" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20705156</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref3"><p id="p-293">
|
|
<strong>Chai 2009</strong>
|
|
</p>Chai, J., Tang, O. S., Hong, Q. Q., Chen, Q. F., Cheng, L. N., Ng, E., Ho, P. C..(2009). A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion, Human Reproduction, 24, 320–324. [<a href="https://pubmed.ncbi.nlm.nih.gov/19049993" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19049993</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref4"><p id="p-294">
|
|
<strong>Dickinson 2014</strong>
|
|
</p>Dickinson, J. E., Jennings, B. G., Doherty, D. A. (2014). Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion: a randomized controlled trial, Obstetrics & GynecologyObstet Gynecol, 123, 1162–8. [<a href="https://pubmed.ncbi.nlm.nih.gov/24807339" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24807339</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref5"><p id="p-295">
|
|
<strong>El-Refaey 1995</strong>
|
|
</p>El-Refaey, H., Templeton, A. (1995). Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: A randomized comparison between two misoprostol regimens, 10, 475–478. [<a href="https://pubmed.ncbi.nlm.nih.gov/7769082" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7769082</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref6"><p id="p-296">
|
|
<strong>Hamoda 2005</strong>
|
|
</p>Hamoda, H., Ashok, P. W., Flett, G. M. M., Templeton, A. (2005). A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks’ gestation, Human Reproduction, 20, 2348–2354. [<a href="https://pubmed.ncbi.nlm.nih.gov/15878927" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15878927</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref7"><p id="p-297">
|
|
<strong>Ho 1997</strong>
|
|
</p>Ho, P. C., Ngai, S. W., Liu, K. L., Wong, G. C. Y., Lee, S. W. H. (1997).Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy, 90, 735–738. [<a href="https://pubmed.ncbi.nlm.nih.gov/9351755" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9351755</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref8"><p id="p-298">
|
|
<strong>Hou 2010</strong>
|
|
</p>Hou,S., Zhang,L., Chen,Q., Fang,A., Cheng,L.(2010). One- and two-day mifepristone-misoprostol intervals for second trimester termination of pregnancy between 13 and 16 weeks of gestation, International Journal of Gynaecology and Obstetrics, 111, 126–130. [<a href="https://pubmed.ncbi.nlm.nih.gov/20705290" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20705290</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref9"><p id="p-299">
|
|
<strong>Mentula 2011</strong>
|
|
</p>Mentula, M, Suhonen, S, Heikinheimo, O. (2011). One- and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancy--a randomized trial, Human reproduction (Oxford, England), 26, 2690–2697. [<a href="https://pubmed.ncbi.nlm.nih.gov/21798991" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21798991</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref10"><p id="p-300">
|
|
<strong>Ngai 2000</strong>
|
|
</p>Ngai, S. W., Tang, O. S., Ho, P. C. (2000). Randomized comparison of vaginal (200 mug every 3 h) and oral (400 mug every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy, Human Reproduction, 15, 2205–2208. [<a href="https://pubmed.ncbi.nlm.nih.gov/11006200" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11006200</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref11"><p id="p-301">
|
|
<strong>RCOG 2011</strong>
|
|
</p>Royal College of Obstetricians and Gynaecologists (2011). The care of women requesting induced abortion: Evidence-based clinical guideline number 7. London: RCOG Press.</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="ch10.s1.1.ref12"><p id="p-302">
|
|
<strong>Tang 2005</strong>
|
|
</p>Tang, O. S., Chan, C. C. W., Kan, A. S. Y., Ho, P. C. (2005). A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks’ gestation, Human Reproduction, 20, 3062–3066. [<a href="https://pubmed.ncbi.nlm.nih.gov/16037110" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16037110</span></a>]</div></p></li></ul></div></div></div><div id="appendixesappgroup10"><h2 id="_appendixesappgroup10_">Appendices</h2><div id="ch10.appa"><h3>Appendix A. Review protocols</h3><div id="ch10.appa.s1"><h4>Review protocol for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch10appatab1"><a href="/books/NBK561115/table/ch10.appa.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figch10appatab1" rid-ob="figobch10appatab1"><img class="small-thumb" src="/books/NBK561115/table/ch10.appa.tab1/?report=thumb" src-large="/books/NBK561115/table/ch10.appa.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ch10.appa.tab1"><a href="/books/NBK561115/table/ch10.appa.tab1/?report=objectonly" target="object" rid-ob="figobch10appatab1">Table</a></h4><p class="float-caption no_bottom_margin">Women who are having a medical termination of pregnancy between 10+1 and 24+0 weeks’ gestation Exclusions:
|
|
-Any studies with an indirect population</p></div></div></div></div><div id="ch10.appb"><h3>Appendix B. Literature search strategies</h3><div id="ch10.appb.s1"><h4>Literature search strategy for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><p>The search for this topic was last run on 14<sup>th</sup> June 2018. It was decided not to undertake a re-run for this topic in November 2018 as this is not a fast moving evidence base and there were unlikely to be any new studies published which would affect the recommendations.</p><p>
|
|
<b>Database: Medline & Embase (Multifile)</b>
|
|
</p><p>Last searched on <b>Embase Classic+Embase</b> 1947 to 2018 June 13, <b>Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)</b> 1946 to Present</p><p id="ch10.appb.tab1"><a href="/books/NBK561115/table/ch10.appb.tab1/?report=objectonly" target="object" rid-ob="figobch10appbtab1" class="figpopup">Date of last search: 14<sup>th</sup> June 2018</a></p><p>
|
|
<b>Database: Cochrane Library via Wiley Online</b>
|
|
</p><p id="ch10.appb.tab2"><a href="/books/NBK561115/table/ch10.appb.tab2/?report=objectonly" target="object" rid-ob="figobch10appbtab2" class="figpopup">Date of last search: 14<sup>th</sup> June 2018</a></p></div></div><div id="ch10.appc"><h3>Appendix C. Clinical evidence study selection</h3><div id="ch10.appc.s1"><h4>Clinical evidence study selection for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><p id="ch10.appc.fig1"><a href="/books/NBK561115/figure/ch10.appc.fig1/?report=objectonly" target="object" rid-ob="figobch10appcfig1" class="figpopup">Figure 1. Study selection flow chart</a></p></div></div><div id="ch10.appd"><h3>Appendix D. Clinical evidence tables</h3><div id="ch10.appd.s1"><h4>Clinical evidence tables for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><p id="ch10.appd.et1"><a href="/books/NBK561115/bin/ch10-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (512K)</span></p></div></div><div id="ch10.appe"><h3>Appendix E. Forest plots</h3><div id="ch10.appe.s1"><h4>Forest plots for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><p>No meta-analysis was undertaken for this review.</p></div></div><div id="ch10.appf"><h3>Appendix F. GRADE tables</h3><div id="ch10.appf.s1"><h4>GRADE tables for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><p id="ch10.appf.tab1"><a href="/books/NBK561115/table/ch10.appf.tab1/?report=objectonly" target="object" rid-ob="figobch10appftab1" class="figpopup">Table 3. Clinical evidence profile: Comparison 1. 200 mcg versus 400 mcg vaginal misoprostol (at 4 hour intervals) 36 to 48 hours after oral mifepristone 200 mg</a></p><p id="ch10.appf.tab2"><a href="/books/NBK561115/table/ch10.appf.tab2/?report=objectonly" target="object" rid-ob="figobch10appftab2" class="figpopup">Table 4. Clinical evidence profile: Comparison 2. Vaginal versus oral misoprostol (400 mcg, at 3 hour intervals up to 4 doses following a loading dose of vaginal misoprostol 600 mcg) 36 to 48 hours after oral mifepristone 600 mg</a></p><p id="ch10.appf.tab3"><a href="/books/NBK561115/table/ch10.appf.tab3/?report=objectonly" target="object" rid-ob="figobch10appftab3" class="figpopup">Table 5. Clinical evidence profile: Comparison 3. Vaginal versus oral misoprostol (400 mcg; at 4 hour intervals for vaginal misoprostol and 3 hour intervals for oral misoprostol, up to 5 doses following a loading dose of vaginal misoprostol 800 mcg) 24 to 48 hours after oral mifepristone 200 mg</a></p><p id="ch10.appf.tab4"><a href="/books/NBK561115/table/ch10.appf.tab4/?report=objectonly" target="object" rid-ob="figobch10appftab4" class="figpopup">Table 6. Clinical evidence profile: Comparison 4. Vaginal versus oral misoprostol (200 mcg; at 3 hour intervals, up to 5 doses) ± placebo 36 to 48 hours after 200 mg oral mifepristone</a></p><p id="ch10.appf.tab5"><a href="/books/NBK561115/table/ch10.appf.tab5/?report=objectonly" target="object" rid-ob="figobch10appftab5" class="figpopup">Table 7. Clinical evidence profile: Comparison 5. Oral versus vaginal misoprostol (400 mcg at 3 hour intervals, up to 5 doses) ± placebo 36 to 48 hours after oral mifepristone 200 mg</a></p><p id="ch10.appf.tab6"><a href="/books/NBK561115/table/ch10.appf.tab6/?report=objectonly" target="object" rid-ob="figobch10appftab6" class="figpopup">Table 8. Clinical evidence profile: Comparison 6. Sublingual versus oral misoprostol (400 mcg; at 3 hour intervals, up to 5 doses following a loading dose of vaginal misoprostol 800 mcg) 24 to 48 hours after oral mifepristone 200 mg</a></p><p id="ch10.appf.tab7"><a href="/books/NBK561115/table/ch10.appf.tab7/?report=objectonly" target="object" rid-ob="figobch10appftab7" class="figpopup">Table 9. Clinical evidence profile: Comparison 7. Sublingual versus oral misoprostol (400 mcg, at 3 hour intervals up to 5 doses) 36 to 48 hours after oral mifepristone 200 mg</a></p><p id="ch10.appf.tab8"><a href="/books/NBK561115/table/ch10.appf.tab8/?report=objectonly" target="object" rid-ob="figobch10appftab8" class="figpopup">Table 10. Clinical evidence profile: Comparison 8. Sublingual (600 mcg; followed by 400 mcg at 3 hour intervals up to 5 doses) versus vaginal (800 mcg; followed by 400 mcg at 3 hour intervals up to 5 doses) misoprostol, 36 to 48 hours after oral mifepristone 200 mg</a></p><p id="ch10.appf.tab9"><a href="/books/NBK561115/table/ch10.appf.tab9/?report=objectonly" target="object" rid-ob="figobch10appftab9" class="figpopup">Table 11. Clinical evidence profile: Comparison 9. Oral misoprostol (400 mcg; every 6 hours, up to 2 doses) 1 versus 2 days after oral mifepristone 200 mg + 600 mcg vaginal misoprostol</a></p><p id="ch10.appf.tab10"><a href="/books/NBK561115/table/ch10.appf.tab10/?report=objectonly" target="object" rid-ob="figobch10appftab10" class="figpopup">Table 12. Clinical evidence profile: Comparison 10. Vaginal misoprostol (400 mcg; at 3 hour intervals, up to 5 doses per 24 hours) 1 versus 2 days after oral mifepristone 200 mg</a></p><p id="ch10.appf.tab11"><a href="/books/NBK561115/table/ch10.appf.tab11/?report=objectonly" target="object" rid-ob="figobch10appftab11" class="figpopup">Table 13. Clinical evidence profile: Comparison 11. Vaginal misoprostol (600 mcg; followed by 400 mcg at 3 hour intervals, up to 4 doses) simultaneous with mifepristone 200 mg versus 36 to 38 hours after 200 mg oral mifepristone</a></p><p id="ch10.appf.tab12"><a href="/books/NBK561115/table/ch10.appf.tab12/?report=objectonly" target="object" rid-ob="figobch10appftab12" class="figpopup">Table 14. Clinical evidence profile: Comparison 12. Buccal misoprostol 400 mcg (at 3 hour intervals) ± placebo simultaneous with mifepristone 200 mg versus 1 day following oral mifepristone 200 mg</a></p></div></div><div id="ch10.appg"><h3>Appendix G. Economic evidence study selection</h3><div id="ch10.appg.s1"><h4>Economic evidence for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><p>No economic evidence was identified which was applicable to this review question.</p></div></div><div id="ch10.apph"><h3>Appendix H. Economic evidence tables</h3><div id="ch10.apph.s1"><h4>Economic evidence tables for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><p>No economic evidence was identified which was applicable to this review question.</p></div></div><div id="ch10.appi"><h3>Appendix I. Economic evidence profiles</h3><div id="ch10.appi.s1"><h4>Economic evidence profiles for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><p>No economic evidence was identified which was applicable to this review question.</p></div></div><div id="ch10.appj"><h3>Appendix J. Economic analysis</h3><div id="ch10.appj.s1"><h4>Economic analysis for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><p>No economic analysis was conducted for this review question.</p></div></div><div id="ch10.appk"><h3>Appendix K. Excluded studies</h3><div id="ch10.appk.s1"><h4>Excluded studies for review question: What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical abortion from 10<sup>+1</sup> to 24<sup>+0</sup> weeks?</h4><div id="ch10.appk.s1.1"><h5>Clinical studies</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch10appktab1"><a href="/books/NBK561115/table/ch10.appk.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figch10appktab1" rid-ob="figobch10appktab1"><img class="small-thumb" src="/books/NBK561115/table/ch10.appk.tab1/?report=thumb" src-large="/books/NBK561115/table/ch10.appk.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ch10.appk.tab1"><a href="/books/NBK561115/table/ch10.appk.tab1/?report=objectonly" target="object" rid-ob="figobch10appktab1">Table</a></h4></div></div></div><div id="ch10.appk.s1.2"><h5>Economic studies</h5><p>No economic evidence was identified for this review. See <a href="/books/NBK561115/bin/bm2.pdf">supplementary material 2</a> for further information.</p></div></div></div><div id="ch10.appl"><h3>Appendix L. Research recommendations</h3><p>No research recommendations were made for this review.</p></div></div><div><h2 id="NBK561115_footnotes">Footnotes</h2><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="ch10.fn1"><p class="no_top_margin">Due to the use of medians for which there are no established or default GRADE MIDs it is unclear whether these differences are clinically important.</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="ch10.fn2"><p class="no_top_margin">Due to the use of medians for which there are no established or default GRADE MIDs it is unclear whether these differences are clinically important.</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="ch10.fn3"><p class="no_top_margin">Due to the use of medians for which there are no established or default GRADE MIDs it is unclear whether these differences are clinically important.</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="ch10.fn4"><p class="no_top_margin">Due to the use of medians for which there are no established or default GRADE MIDs it is unclear whether these differences are clinically important.</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="ch10.fn5"><p class="no_top_margin">Due to the use of medians for which there are no established or default GRADE MIDs it is unclear whether these differences are clinically important.</p></div></dd></dl><dl class="bkr_refwrap"><dt>f</dt><dd><div id="ch10.fn6"><p class="no_top_margin">Due to the use of medians for which there are no established or default GRADE MIDs it is unclear whether these differences are clinically important.</p></div></dd></dl><dl class="bkr_refwrap"><dt>g</dt><dd><div id="ch10.fn7"><p class="no_top_margin">Due to the use of medians for which there are no established or default GRADE MIDs it is unclear whether these differences are clinically important.</p></div></dd></dl></dl></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Evidence reviews</p><p>These evidence reviews were developed by the National Guideline Alliance hosted by the Royal College of Obstetricians and Gynaecologists</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2019.</div><div class="small"><span class="label">Bookshelf ID: NBK561115</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32813465" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">32813465</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobch10tab1"><div id="ch10.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">Summary of the protocol (PICO table)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.tab1_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ch10.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_ch10.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Women who are having a medical termination of pregnancy between 10<sup>+0</sup> and 24<sup>+0</sup> weeks’ gestation</td></tr><tr><th id="hd_b_ch10.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</th><td headers="hd_b_ch10.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Route of misoprostol administration:
|
|
<ul id="l389"><li id="lt983" class="half_rhythm"><div>Vaginal</div></li><li id="lt984" class="half_rhythm"><div>Oral</div></li><li id="lt985" class="half_rhythm"><div>Sublingual</div></li><li id="lt986" class="half_rhythm"><div>Buccal</div></li></ul>
|
|
Dose of misoprostol:
|
|
<ul id="l390"><li id="lt987" class="half_rhythm"><div>200 micrograms (mcg)</div></li><li id="lt988" class="half_rhythm"><div>400 mcg</div></li><li id="lt989" class="half_rhythm"><div>600 mcg</div></li><li id="lt990" class="half_rhythm"><div>800 mcg</div></li></ul>
|
|
Dose interval</td></tr><tr><th id="hd_b_ch10.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison</th><td headers="hd_b_ch10.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All combinations of the routes of administration, doses, number of doses, and dosing intervals listed above will be compared.</td></tr><tr><th id="hd_b_ch10.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome</th><td headers="hd_b_ch10.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Critical outcomes:</b>
|
|
<ul id="l391"><li id="lt991" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt992" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt993" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li></ul>
|
|
<b>Important outcomes:</b>
|
|
<ul id="l392"><li id="lt994" class="half_rhythm"><div>Haemorrhage requiring transfusion or >500 ml of blood loss</div></li><li id="lt995" class="half_rhythm"><div>Vomiting</div></li><li id="lt996" class="half_rhythm"><div>Patient satisfaction</div></li><li id="lt997" class="half_rhythm"><div>Diarrhoea</div></li></ul></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">mcg: micrograms</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10tab2"><div id="ch10.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of included studies</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study and setting</th><th id="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention/ comparison</th><th id="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th></tr></thead><tbody><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>Vietnam</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=505</p>
|
|
<p>Women with a live foetus eligible for medical abortion, with closed cervical os, no vaginal bleeding and no contraindications to study drugs 13 to 22 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>Simultaneous administration of mifepristone and misoprostol:</b>
|
|
</p>
|
|
<p>Placebo followed 24 hours later by 200 mg mifepristone and 400 mcg buccal misoprostol followed by 400 mcg buccal misoprostol every 3 hours until expulsion of foetus or 48 hours</p>
|
|
<p>
|
|
<b>24 hour interval between mifepristone and misoprostol:</b>
|
|
</p>
|
|
<p>200 mg mifepristone followed 24 hours later by 200 mg placebo and 400 mcg buccal misoprostol followed by 400 mcg buccal misoprostol every 3 hours until expulsion of foetus or 48 hours</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l393"><li id="lt998" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt999" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1000" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li><li id="lt1001" class="half_rhythm"><div>Haemorrhage requiring transfusion or >500 ml of blood loss</div></li><li id="lt1002" class="half_rhythm"><div>Vomiting</div></li><li id="lt1003" class="half_rhythm"><div>Patient satisfaction</div></li><li id="lt1004" class="half_rhythm"><div>Diarrhoea</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref2" rid="ch10.s1.1.ref2">Brouns 2010</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>The Netherlands</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n =176</p>
|
|
<p>Women requesting abortion</p>
|
|
<p>14 to 24 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>200 mcg vaginal misoprostol:</b> 200 mcg vaginal misoprostol at 4 hour intervals, 36 to 48 hours following oral mifepristone 200 mg</p>
|
|
<p><b>400 mcg vaginal misoprostol:</b> 400 mcg vaginal misoprostol at 4 hour intervals, 36 to 48 hours following oral mifepristone 200 mg</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l394"><li id="lt1005" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1006" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1007" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li><li id="lt1008" class="half_rhythm"><div>Haemorrhage requiring transfusion or >500 ml of blood loss</div></li><li id="lt1009" class="half_rhythm"><div>Vomiting</div></li><li id="lt1010" class="half_rhythm"><div>Diarrhoea</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref3" rid="ch10.s1.1.ref3">Chai 2009</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>China</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=141</p>
|
|
<p>Healthy women, more than 18 years old, requesting abortion and willing to comply with follow to up</p>
|
|
<p>12 to 20 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>Simultaneous administration of mifepristone and misoprostol:</b>
|
|
</p>
|
|
<p>200 mg mifepristone orally followed by 600 mcg vaginal misoprostol immediately, which was then followed by 400 mcg vaginal misoprostol every 3 hours up to 4 doses</p>
|
|
<p>
|
|
<b>36 to 38 hour interval between mifepristone and misoprostol:</b>
|
|
</p>
|
|
<p>200 mg mifepristone orally followed by 600 mcg vaginal misoprostol 36 to 38 hours later followed by 400 mcg vaginal misoprostol every 3 hours up to 4 doses</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l395"><li id="lt1011" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1012" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1013" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li><li id="lt1014" class="half_rhythm"><div>Haemorrhage requiring transfusion or >500 ml of blood loss</div></li><li id="lt1015" class="half_rhythm"><div>Diarrhoea</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref4" rid="ch10.s1.1.ref4">Dickinson 2014</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>Australia</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=302</p>
|
|
<p>Women requesting a second trimester medical abortion for foetal abnormality or maternal medical complication</p>
|
|
<p>14 to 24 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Oral misoprostol:</b> mifepristone 200 mg followed 24 to 48 hours later by 800 mcg vaginal misoprostol followed by 400 mcg oral misoprostol every 3 hours up to 5 doses</p>
|
|
<p><b>Vaginal misoprostol:</b> mifepristone 200 mg followed 24 to 48 hours later by 800 mcg vaginal misoprostol followed by 400 mcg vaginal misoprostol every 4 hours up to 5 doses</p>
|
|
<p><b>Sublingual misoprostol:</b> mifepristone 200 mg followed 24 to 48 hours later by 800 mcg vaginal misoprostol followed by 400 mcg sublingual misoprostol every 3 hours up to 5 doses</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l396"><li id="lt1016" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1017" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1018" class="half_rhythm"><div>Haemorrhage requiring transfusion or >500 ml of blood loss</div></li><li id="lt1019" class="half_rhythm"><div>Patient satisfaction</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref5" rid="ch10.s1.1.ref5">El-Refaey 1995</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>United Kingdom</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=69</p>
|
|
<p>Women requesting abortion for socioeconomic reasons</p>
|
|
<p>13 to 20 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Vaginal misoprostol:</b> 600 mg mifepristone orally followed by 600 mcg vaginal misoprostol 36 to 48 hours later and then misoprostol 400 mcg vaginal every 3 hours up to 4 doses.</p>
|
|
<p><b>Oral misoprostol:</b> 600 mg mifepristone orally followed by 600 mcg vaginal misoprostol 36 to 48 hours later and then 400 mcg oral misoprostol every 3 hours up to 4 doses.</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l397"><li id="lt1020" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1021" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1022" class="half_rhythm"><div>Haemorrhage requiring transfusion or >500 ml of blood loss</div></li><li id="lt1023" class="half_rhythm"><div>Vomiting</div></li><li id="lt1024" class="half_rhythm"><div>Diarrhoea</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref6" rid="ch10.s1.1.ref6">Hamoda 2005</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>United Kingdom</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=76</p>
|
|
<p>Women with viable singleton pregnancies requesting medical abortion</p>
|
|
<p>13 to 20 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Sublingual misoprostol:</b> 200 mg mifepristone followed 36 to 48 hours later by 600 mcg sublingual misoprostol. Further 3 hourly doses of 400 mcg sublingual misoprostol up to 5 doses</p>
|
|
<p><b>Vaginal misoprostol:</b> 200 mg mifepristone followed 36 to 48 hours later by vaginal misoprostol 800 mcg. Further 3 hourly doses of 400 mcg vaginal misoprostol up to 5 doses</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l398"><li id="lt1025" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1026" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li><li id="lt1027" class="half_rhythm"><div>Vomiting</div></li><li id="lt1028" class="half_rhythm"><div>Patient satisfaction</div></li><li id="lt1029" class="half_rhythm"><div>Diarrhoea</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref7" rid="ch10.s1.1.ref7">Ho 1997</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>China</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=98</p>
|
|
<p>Healthy women aged 16 to 35 years with singleton pregnancies</p>
|
|
<p>14 to 20 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Oral misoprostol:</b> 200 mg mifepristone followed 36 to 48 hours later by 200 mcg oral misoprostol and vaginal placebo every 3 hours up to 5 doses</p>
|
|
<p><b>Vaginal misoprostol:</b> 200 mg mifepristone followed 36 to 48 hours later by 200 mcg misoprostol vaginally and a placebo orally every 3 hours up to 5 doses</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l399"><li id="lt1030" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1031" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1032" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li><li id="lt1033" class="half_rhythm"><div>Vomiting</div></li><li id="lt1034" class="half_rhythm"><div>Diarrhoea</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref8" rid="ch10.s1.1.ref8">Hou 2010</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>China</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=100</p>
|
|
<p>Healthy women aged 18 to 45 years requesting abortion and willing to comply with follow-up visits</p>
|
|
<p>13 to 16 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>1 day interval</b>: 200 mg oral mifepristone followed 1 day later by 600 mcg vaginal misoprostol and 400 mcg oral misoprostol every 6 hours up to 2 doses</p>
|
|
<p><b>2 day interval</b>: 200 mg oral mifepristone followed 2 days later by 600 mcg vaginal misoprostol and 400 mcg oral misoprostol every 6 hours up to 2 doses</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l400"><li id="lt1035" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1036" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1037" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li><li id="lt1038" class="half_rhythm"><div>Vomiting</div></li><li id="lt1039" class="half_rhythm"><div>Diarrhoea</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref9" rid="ch10.s1.1.ref9">Mentula 2011</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>Finland</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=227</p>
|
|
<p>Women more than 18 years age, with a viable singleton pregnancy and a legal indication for abortion</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>1 day interval</b>: 200 mg mifepristone oral followed by 400 mcg vaginal misoprostol 20 to 28 hours later and then every 3 hours, for up to 5 doses per 24 hours</p>
|
|
<p><b>2 day interval:</b> 200 mg mifepristone orally followed by 400 mcg vaginal misoprostol 2 days (40 to 48 hours) later and every 3 hours with up to 5 doses per 24 hours</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l401"><li id="lt1040" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1041" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li><li id="lt1042" class="half_rhythm"><div>Haemorrhage requiring transfusion or >500 ml of blood loss</div></li><li id="lt1043" class="half_rhythm"><div>Vomiting</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref10" rid="ch10.s1.1.ref10">Ngai 2000</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>China</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=139</p>
|
|
<p>Healthy women aged 16 to 35 years requesting legal abortion</p>
|
|
<p>14 to 20 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Oral misoprostol 400 mcg:</b> 200 mg mifepristone oral followed 36 to 48 hours later by 400 mcg oral misoprostol every 3 hours up to 5 doses + vaginal vitamin B6 placebo</p>
|
|
<p><b>Vaginal misoprostol 200 mcg:</b> 200 mg mifepristone oral followed 36 to 48 hours later by 200 mcg vaginal misoprostol every 3 hours up to 5 doses + oral vitamin B6 placebo</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l402"><li id="lt1044" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1045" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1046" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li><li id="lt1047" class="half_rhythm"><div>Vomiting</div></li><li id="lt1048" class="half_rhythm"><div>Diarrhoea</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_ch10.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<a class="bibr" href="#ch10.s1.1.ref12" rid="ch10.s1.1.ref12">Tang 2005</a>
|
|
</p>
|
|
<p>RCT</p>
|
|
<p>China</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=118</p>
|
|
<p>Women more than 18 years old, requesting a legal abortion</p>
|
|
<p>12 to 20 weeks’ gestation</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Sublingual misoprostol</b>: 200 mg mifepristone oral followed 36 to 48 hours later by sublingual misoprostol 400 mcg every 3 hours up to 5 doses</p>
|
|
<p><b>Oral misoprostol</b>: 200 mg oral mifepristone followed 36 to 48 hours later by oral misoprostol 400 mcg every 3 hours up to 5 doses</p>
|
|
</td><td headers="hd_h_ch10.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="l403"><li id="lt1049" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1050" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1051" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li><li id="lt1052" class="half_rhythm"><div>Diarrhoea</div></li></ul>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">mcg: micrograms; RCT: randomised controlled trial</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appatab1"><div id="ch10.appa.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appa.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Field (based on <a href="http://www.prisma-statement.org/Extensions/Protocols.aspx" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PRISMA-P</a></th><th id="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Content</th></tr></thead><tbody><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question in SCOPE</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">What is the optimal dose and route of administration of misoprostol after mifepristone, for inducing medical termination in the second trimester?</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question in guideline</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">What is the optimal regimen and route of administration of misoprostol after mifepristone, for inducing medical termination from 10+1 to 24+0 weeks</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Type of review question</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Objective of the review</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To determine the optimal regimen and route of administration for misoprostol (after mifepristone) between 10+1 and 24+0 weeks’ gestation</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – population</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Women who are having a medical termination of pregnancy between 10+1 and 24+0 weeks’ gestation</p>
|
|
<p>Exclusions:
|
|
<dl id="l404" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1053"><p class="no_top_margin">Any studies with an indirect population</p></dd></dl></dl></p>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – intervention(s)</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Route of misoprostol administration:
|
|
<ul id="l405"><li id="lt1054" class="half_rhythm"><div>Vaginal</div></li><li id="lt1055" class="half_rhythm"><div>Oral</div></li><li id="lt1056" class="half_rhythm"><div>Sublingual</div></li><li id="lt1057" class="half_rhythm"><div>Buccal</div></li></ul>
|
|
Dose of misoprostol:
|
|
<ul id="l406"><li id="lt1058" class="half_rhythm"><div>200 mcg</div></li><li id="lt1059" class="half_rhythm"><div>400 mcg</div></li><li id="lt1060" class="half_rhythm"><div>600 mcg</div></li><li id="lt1061" class="half_rhythm"><div>800 mcg</div></li></ul>
|
|
Dose interval</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – comparator(s)/control</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All combinations of the routes of administration, doses, number of doses, and dosing intervals listed above will be compared.</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes and prioritisation</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Critical outcomes:</b>
|
|
<ul id="l407"><li id="lt1062" class="half_rhythm"><div>Time to expulsion</div></li><li id="lt1063" class="half_rhythm"><div>Complete abortion without the need for surgical intervention</div></li><li id="lt1064" class="half_rhythm"><div>Incomplete abortion with the need for surgical intervention</div></li></ul>
|
|
<b>Important outcomes:</b>
|
|
<ul id="l408"><li id="lt1065" class="half_rhythm"><div>Haemorrhage requiring transfusion or > 500 ml of blood loss</div></li><li id="lt1066" class="half_rhythm"><div>Vomiting</div></li><li id="lt1067" class="half_rhythm"><div>Patient satisfaction</div></li><li id="lt1068" class="half_rhythm"><div>Diarrhoea</div></li></ul></td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – study design</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<dl id="l409" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1069"><p class="no_top_margin">Systematic reviews of RCTs</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1070"><p class="no_top_margin">RCTs</p></dd></dl></dl>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other inclusion exclusion criteria</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inclusion:
|
|
<dl id="l410" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1071"><p class="no_top_margin">English-language</p></dd></dl></dl></td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proposed sensitivity/sub-group analysis, or meta-regression</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Stratified analyses based on the following sub-groups of women, where possible:</p>
|
|
<p>Medical conditions:
|
|
<dl id="l411" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1072"><p class="no_top_margin">Complex pre-existing medical conditions</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1073"><p class="no_top_margin">No complex pre-existing medical conditions</p></dd></dl></dl>
|
|
Gestational age:
|
|
<dl id="l412" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1074"><p class="no_top_margin">10+1 weeks to 13+6 weeks</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1075"><p class="no_top_margin">14+0 weeks to 24+0 weeks</p></dd></dl></dl>
|
|
Caesarean section:
|
|
<dl id="l413" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1076"><p class="no_top_margin">Previous caesarean section</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1077"><p class="no_top_margin">No previous caesarean section</p></dd></dl></dl>
|
|
Parity:
|
|
<dl id="l414" class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1078"><p class="no_top_margin">Nulliparous</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd id="lt1079"><p class="no_top_margin">Parous</p></dd></dl></dl></p>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selection process – duplicate screening/selection/analysis</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Dual weeding will not be performed for this question</p>
|
|
<p>Sifting, data extraction, appraisal of methodological quality and GRADE assessment will be performed by the systematic reviewer.</p>
|
|
<p>Quality control will be performed by the senior systematic reviewer.</p>
|
|
<p>Dual data extraction will not be performed for this question.</p>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data management (software)</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).</p>
|
|
<p>‘GRADEpro’ will be used to assess the quality of evidence for each outcome.</p>
|
|
<p>NGA STAR software will be used for study sifting, data extraction, recording quality assessment using checklists and generating bibliographies/citations,</p>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Information sources – databases and dates</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Sources to be searched: Medline, Medline In-Process, CCTR, CDSR, DARE, HTA, Embase</p>
|
|
<p>Limits (e.g. date, study design):</p>
|
|
<p>Apply standard animal/non-English language exclusion</p>
|
|
<p>Limit to RCTs and systematic reviews</p>
|
|
<p>Dates: from 1985</p>
|
|
<p>Only studies conducted from 1985 onwards will be considered for this review question, as mifepristone was made available in the UK in 1991 and evidence to support the use of mifepristone in practice is unlikely to be more than 5 years before its licensing in 1991.</p>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Identify if an update</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not an update</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Author contacts</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see the guideline in development web site.</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Highlight if amendment to previous protocol</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see Section 4.5 of <a href="https://www.nice.org.uk/article/pmg20/chapter/4-Developing-review-questions-and-planning-the-evidence-review#planning-the-evidence-review" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search strategy – for one database</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see <a href="#ch10.appb">appendix B</a></td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data collection process – forms/duplicate</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A standardised evidence table format will be used, and published as <a href="#ch10.appd">appendix D</a> (clinical evidence tables) or <a href="#ch10.apph">appendix H</a> (economic evidence tables).</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data items – define all variables to be collected</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see evidence tables in <a href="#ch10.appd">appendix D</a> (clinical evidence tables) or <a href="#ch10.apph">appendix H</a> (economic evidence tables).</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for assessing bias at outcome/study level</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Standard study checklists will be used to critically appraise individual studies. For details please see section 6.2 of Developing NICE guidelines: the manual</p>
|
|
<p>Appraisal of methodological quality:</p>
|
|
<p>The methodological quality of each study will be assessed using an appropriate checklist:
|
|
<ul id="l415"><li id="lt1080" class="half_rhythm"><div>RoBIS for systematic reviews</div></li><li id="lt1081" class="half_rhythm"><div>Cochrane risk of bias tool for RCTs</div></li></ul>
|
|
The risk of bias across all available evidence will be evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.gradeworkinggroup.org/</a></p>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Criteria for quantitative synthesis (where suitable)</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see Section 6.4 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for analysis – combining studies and exploring (in)consistency</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Synthesis of data:</p>
|
|
<p>Pairwise meta-analysis will be conducted where appropriate for all other outcomes.</p>
|
|
<p>When meta-analysing continuous data, change scores will be pooled in preference to final scores.</p>
|
|
<p>For details regarding inconsistency, please see the <a href="/books/NBK561115/bin/bm1.pdf">methods</a> chapter</p>
|
|
<p>Minimally important differences:</p>
|
|
<p>‘Haemorrhage requiring transfusion or >500 loss’: Statistical significance</p>
|
|
<p>‘Complete abortion without the need for surgical intervention’: 3% (with the upper limit of the 95% CI ≤ 5%)</p>
|
|
<p>All other outcomes default values will be used of: 0.8 and 1.25 for dichotomous outcomes (relative risks); 0.5 times SD (of the control group) for continuous outcomes</p>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-bias assessment – publication bias, selective reporting bias</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>For details please see Section 6.2 of Developing NICE guidelines: the manual.</p>
|
|
<p>If sufficient relevant RCT evidence is available, publication bias will be explored using RevMan software to examine funnel plots.</p>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assessment of confidence in cumulative evidence</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see Sections 6.4 and 9.1 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rationale/context – Current management</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see the introduction to the evidence review.</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describe contributions of authors and guarantor</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>A multidisciplinary committee developed the guideline. The committee was convened by The National Guideline Alliance and chaired by Profession Iain Cameron in line with section 3 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
<p>Staff from The National Guideline Alliance will undertake systematic literature searches, appraise the evidence, conduct meta-analysis and cost-effectiveness analysis where appropriate, and draft the guideline in collaboration with the committee. For details please see the <a href="/books/NBK561115/bin/bm1.pdf">methods</a> chapter.</p>
|
|
</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sources of funding/support</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The National Guideline Alliance is funded by NICE and hosted by the Royal College of Obstetricians and Gynaecologists</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Name of sponsor</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The National Guideline Alliance is funded by NICE and hosted by the Royal College of Obstetricians and Gynaecologists</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roles of sponsor</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NICE funds The National Guideline Alliance to develop guidelines for those working in the NHS, public health, and social care in England</td></tr><tr><td headers="hd_h_ch10.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROSPERO registration number</td><td headers="hd_h_ch10.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not registered</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; mcg: micrograms; NHS: National Health Service; NICE: National Institute for Health and Care Excellence; NGA: National Guideline Alliance; RCT: randomised controlled trial; RoBIS: risk of bias in systematic reviews; SD: standard deviation</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appbtab1"><div id="ch10.appb.tab1" class="table"><h3><span class="title">Date of last search: 14<sup>th</sup> June 2018</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#</th><th id="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Searches</th></tr></thead><tbody><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp abortion/ use emczd</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp pregnancy termination/ use emczd</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Abortion, Induced/ use ppez</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abortion Applicants/ use ppez</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Abortion, Spontaneous/ use ppez</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Abortion, Criminal/ use ppez</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aborted fetus/ use ppez</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">fetus death/ use emczd</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">abortion.mp.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(abort$ or postabort$ or preabort$).mp.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((f?etal$ or f?etus$ or gestat$ or midtrimester$ or pregnan$ or prenatal$ or pre natal$ or trimester$) and terminat$).mp.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((f?etal$ or f?etus$) adj loss$).mp.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((gestat$ or midtrimester$ or pregnan$ or prenatal$ or pre natal$ or trimester$) adj3 loss$).mp.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((elective$ or threaten$ or voluntar$) adj3 interrupt$) and pregnan$).mp.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Misoprostol/ use ppez</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">misoprostol/ use emczd</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(misoprostol$ or cytotec$ or arthrotec$ or oxaprost$ or cyprostol$ or mibetec$ or prostokos$ or misotrol$).mp.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 or 17 or 18</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(controlled clinical trial or pragmatic clinical trial or randomized controlled trial).pt. or drug therapy.fs. or (groups or placebo or randomi#ed or randomly or trial).ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">crossover procedure/ or double blind procedure/ or randomized controlled trial/ or single blind procedure/ or (assign* or allocat* or crossover* or cross over* or ((doubl* or singl*) adj blind*) or factorial* or placebo* or random* or volunteer*).ti,ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">meta-analysis/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">meta-analysis as topic/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">systematic review/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">meta-analysis/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(meta analy* or metanaly* or metaanaly*).ti,ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic or evidence) adj2 (review* or overview*)).ti,ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic* or evidence*) adj2 (review* or overview*)).ti,ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search strategy or search criteria or systematic search or study selection or data extraction).ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search* adj4 literature).ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cochrane.jw.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((pool* or combined) adj2 (data or trials or studies or results)).ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 or 36 or 37 or 38 or 39 or 40 or 41 or 42</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43 not 44</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 or 46 or 47 or 48 or 49 or 50 or 51</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/ or case study/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53 or 54 or 55 or 56 or 57</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58 not 59</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">nonhuman/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental Animal/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal model/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60 or 61 or 62 or 63 or 64 or 65 or 66 or 67</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52 use ppez</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68 use emczd</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69 or 70</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 use ppez</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21 use emczd</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72 or 73</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or/22-23,26,28-33) use ppez</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or/24-27,29-34) use emczd</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75 or 76</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 and 19</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71 and 78</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78 not 79</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74 or 77</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80 and 81</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">remove duplicates from 82</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 83 to english language</td></tr><tr><td headers="hd_h_ch10.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85</td><td headers="hd_h_ch10.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 84 to yr="1985 -Current”</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch10appbtab2"><div id="ch10.appb.tab2" class="table"><h3><span class="title">Date of last search: 14<sup>th</sup> June 2018</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appb.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#</th><th id="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Searches</th></tr></thead><tbody><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Abortion, Induced] explode all trees</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Abortion Applicants] explode all trees</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Abortion, Spontaneous] explode all trees</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Abortion, Criminal] explode all trees</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Aborted Fetus] explode all trees</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“abortion":ti,ab,kw (Word variations have been searched)</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(abort* or postabort* or preabort*):ti,ab,kw (Word variations have been searched)</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((fetal* or fetus* or foetal* or foetus* or gestat* or midtrimester* or pregnan* or prenatal* or pre natal* or trimester*) and terminat*):ti,ab,kw (Word variations have been searched)</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((fetal* or fetus* or foetal* or foetus*) next loss*):ti,ab,kw (Word variations have been searched)</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((gestat* or midtrimester* or pregnan* or prenatal* or pre natal* or trimester*) near/3 loss*):ti,ab,kw (Word variations have been searched)</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((elective* or threaten* or voluntar*) near/3 interrupt*) and pregnan*):ti,ab,kw (Word variations have been searched)</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#12</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#13</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Misoprostol] this term only</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#14</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(misoprostol* or cytotec* or arthrotec* or oxaprost* or cyprostol* or mibetec* or prostokos* or misotrol*):ti,ab,kw (Word variations have been searched)</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#15</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#13 or #14</td></tr><tr><td headers="hd_h_ch10.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#16</td><td headers="hd_h_ch10.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#12 and #15</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobch10appcfig1"><div id="ch10.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Study%20selection%20flow%20chart.&p=BOOKS&id=561115_ch10appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK561115/bin/ch10appcf1.jpg" alt="Figure 1. Study selection flow chart." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Study selection flow chart</span></h3></div></article><article data-type="table-wrap" id="figobch10appftab1"><div id="ch10.appf.tab1" class="table"><h3><span class="label">Table 3</span><span class="title">Clinical evidence profile: Comparison 1. 200 mcg versus 400 mcg vaginal misoprostol (at 4 hour intervals) 36 to 48 hours after oral mifepristone 200 mg</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab1_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab1_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab1_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab1_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab1_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab1_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab1_1_1_1_1" id="hd_h_ch10.appf.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab1_1_1_1_1" id="hd_h_ch10.appf.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab1_1_1_1_1" id="hd_h_ch10.appf.tab1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab1_1_1_1_1" id="hd_h_ch10.appf.tab1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab1_1_1_1_1" id="hd_h_ch10.appf.tab1_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab1_1_1_1_1" id="hd_h_ch10.appf.tab1_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab1_1_1_1_1" id="hd_h_ch10.appf.tab1_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab1_1_1_1_2" id="hd_h_ch10.appf.tab1_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">200 mcg vaginal misoprostol</th><th headers="hd_h_ch10.appf.tab1_1_1_1_2" id="hd_h_ch10.appf.tab1_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">400 mcg vaginal misoprostol</th><th headers="hd_h_ch10.appf.tab1_1_1_1_3" id="hd_h_ch10.appf.tab1_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab1_1_1_1_3" id="hd_h_ch10.appf.tab1_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_h_ch10.appf.tab1_1_1_2_3 hd_h_ch10.appf.tab1_1_1_2_4 hd_h_ch10.appf.tab1_1_1_2_5 hd_h_ch10.appf.tab1_1_1_2_6 hd_h_ch10.appf.tab1_1_1_2_7 hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_h_ch10.appf.tab1_1_1_2_9 hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_h_ch10.appf.tab1_1_1_2_11 hd_h_ch10.appf.tab1_1_1_1_4 hd_h_ch10.appf.tab1_1_1_1_5" id="hd_b_ch10.appf.tab1_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref2" rid="ch10.s1.1.ref2">Brouns 2010</a>)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_3 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_4 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_5 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_6 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_7 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 9.2 (7.1 to 11.3; n=86)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_9 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 8.0 (7.1 to 8.9; n=90)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_11 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab1_1_1_1_4 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab1_1_1_1_5 hd_b_ch10.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_h_ch10.appf.tab1_1_1_2_3 hd_h_ch10.appf.tab1_1_1_2_4 hd_h_ch10.appf.tab1_1_1_2_5 hd_h_ch10.appf.tab1_1_1_2_6 hd_h_ch10.appf.tab1_1_1_2_7 hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_h_ch10.appf.tab1_1_1_2_9 hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_h_ch10.appf.tab1_1_1_2_11 hd_h_ch10.appf.tab1_1_1_1_4 hd_h_ch10.appf.tab1_1_1_1_5" id="hd_b_ch10.appf.tab1_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Complete abortion without the need for surgical intervention (follow-up mean 48 hours)</th></tr><tr><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref2" rid="ch10.s1.1.ref2">Brouns 2010</a>)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_3 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_4 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_5 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_6 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_7 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>57/86</p>
|
|
<p>(66.3%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_9 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>66/90</p>
|
|
<p>(73.3%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.9 (0.74 to 1.1)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_11 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73 fewer per 1000 (from 191 fewer to 73 more)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_4 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab1_1_1_1_5 hd_b_ch10.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_h_ch10.appf.tab1_1_1_2_3 hd_h_ch10.appf.tab1_1_1_2_4 hd_h_ch10.appf.tab1_1_1_2_5 hd_h_ch10.appf.tab1_1_1_2_6 hd_h_ch10.appf.tab1_1_1_2_7 hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_h_ch10.appf.tab1_1_1_2_9 hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_h_ch10.appf.tab1_1_1_2_11 hd_h_ch10.appf.tab1_1_1_1_4 hd_h_ch10.appf.tab1_1_1_1_5" id="hd_b_ch10.appf.tab1_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Incomplete abortion with the need for surgical intervention</th></tr><tr><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref2" rid="ch10.s1.1.ref2">Brouns 2010</a>)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_3 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_4 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_5 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_6 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_7 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>29/86</p>
|
|
<p>(33.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_9 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>24/90</p>
|
|
<p>(26.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.26 (0.8 to 1.99)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_11 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69 more per 1000 (from 53 fewer to 264 more)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_4 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab1_1_1_1_5 hd_b_ch10.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_h_ch10.appf.tab1_1_1_2_3 hd_h_ch10.appf.tab1_1_1_2_4 hd_h_ch10.appf.tab1_1_1_2_5 hd_h_ch10.appf.tab1_1_1_2_6 hd_h_ch10.appf.tab1_1_1_2_7 hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_h_ch10.appf.tab1_1_1_2_9 hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_h_ch10.appf.tab1_1_1_2_11 hd_h_ch10.appf.tab1_1_1_1_4 hd_h_ch10.appf.tab1_1_1_1_5" id="hd_b_ch10.appf.tab1_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Haemorrhage requiring transfusion or >500 ml of blood loss</th></tr><tr><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref2" rid="ch10.s1.1.ref2">Brouns 2010</a>)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_3 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_4 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_5 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_6 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>5</sup></td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_7 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4/86</p>
|
|
<p>(4.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_9 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3/90</p>
|
|
<p>(3.3%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.4 (0.32 to 6.05)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_11 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 more per 1000 (from 23 fewer to 168 more)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_4 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab1_1_1_1_5 hd_b_ch10.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_h_ch10.appf.tab1_1_1_2_3 hd_h_ch10.appf.tab1_1_1_2_4 hd_h_ch10.appf.tab1_1_1_2_5 hd_h_ch10.appf.tab1_1_1_2_6 hd_h_ch10.appf.tab1_1_1_2_7 hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_h_ch10.appf.tab1_1_1_2_9 hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_h_ch10.appf.tab1_1_1_2_11 hd_h_ch10.appf.tab1_1_1_1_4 hd_h_ch10.appf.tab1_1_1_1_5" id="hd_b_ch10.appf.tab1_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Vomiting</th></tr><tr><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref2" rid="ch10.s1.1.ref2">Brouns 2010</a>)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_3 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_4 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_5 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_6 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>5</sup></td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_7 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>27/86</p>
|
|
<p>(31.4%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_9 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>37/90</p>
|
|
<p>(41.1%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.76 (0.51 to 1.14)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_11 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">99 fewer per 1000 (from 201 fewer to 58 more)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_4 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab1_1_1_1_5 hd_b_ch10.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_h_ch10.appf.tab1_1_1_2_3 hd_h_ch10.appf.tab1_1_1_2_4 hd_h_ch10.appf.tab1_1_1_2_5 hd_h_ch10.appf.tab1_1_1_2_6 hd_h_ch10.appf.tab1_1_1_2_7 hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_h_ch10.appf.tab1_1_1_2_9 hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_h_ch10.appf.tab1_1_1_2_11 hd_h_ch10.appf.tab1_1_1_1_4 hd_h_ch10.appf.tab1_1_1_1_5" id="hd_b_ch10.appf.tab1_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Diarrhoea</th></tr><tr><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_1 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref2" rid="ch10.s1.1.ref2">Brouns 2010</a>)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_2 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_3 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_4 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_5 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_6 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab1_1_1_1_1 hd_h_ch10.appf.tab1_1_1_2_7 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_8 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5/86</p>
|
|
<p>(5.8%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_2 hd_h_ch10.appf.tab1_1_1_2_9 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10/90</p>
|
|
<p>(11.1%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_10 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.52 (0.19 to 1.47)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_3 hd_h_ch10.appf.tab1_1_1_2_11 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53 fewer per 1000 (from 90 fewer to 52 more)</td><td headers="hd_h_ch10.appf.tab1_1_1_1_4 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab1_1_1_1_5 hd_b_ch10.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab1_1"><p class="no_margin">As this outcome is only reported as medians and ranges for which there are no established or default GRADE MIDs, the imprecision ratings were undertaken by using the optimum information size so that if the total n≥400, then the quality was not downgraded, if n=200-399, then the quality was downgraded by 1 level and if the total n<200, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab1_2"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (hours), not means and standard deviations, which were: 200 mcg: Median (range) 9.2 (7.1 to 11.3; n=86); 400 mcg: Median (range) 8.0 (7.1 to 8.9; n=90); p < 0.05 (log rank test)</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab1_3"><p class="no_margin">The MID for this outcome is 3%, and the imprecision ratings were undertaken on that basis by using the absolute effect estimates so that if the CI crosses 30 fewer (3% of 1000) or 30 more, then the quality was downgraded by 1 level. If the CI crosses both, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab1_4"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch10.appf.tab1_5"><p class="no_margin">The MID for this outcome is statistical significance, and the imprecision ratings were undertaken on that basis by using the optimum information size so that if the total event rate ≥300, then the quality was not downgraded, if the event rate = 150-299, then the quality was downgraded by 1 level and if the event rate <150, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="ch10.appf.tab1_6"><p class="no_margin">The quality of evidence was downgraded by 1 level as the 95% confidence interval crosses 1 MID</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab2"><div id="ch10.appf.tab2" class="table"><h3><span class="label">Table 4</span><span class="title">Clinical evidence profile: Comparison 2. Vaginal versus oral misoprostol (400 mcg, at 3 hour intervals up to 4 doses following a loading dose of vaginal misoprostol 600 mcg) 36 to 48 hours after oral mifepristone 600 mg</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab2_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab2_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab2_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab2_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab2_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab2_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab2_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab2_1_1_1_1" id="hd_h_ch10.appf.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab2_1_1_1_1" id="hd_h_ch10.appf.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab2_1_1_1_1" id="hd_h_ch10.appf.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab2_1_1_1_1" id="hd_h_ch10.appf.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab2_1_1_1_1" id="hd_h_ch10.appf.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab2_1_1_1_1" id="hd_h_ch10.appf.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab2_1_1_1_1" id="hd_h_ch10.appf.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab2_1_1_1_2" id="hd_h_ch10.appf.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vaginal misoprostol</th><th headers="hd_h_ch10.appf.tab2_1_1_1_2" id="hd_h_ch10.appf.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral misoprostol</th><th headers="hd_h_ch10.appf.tab2_1_1_1_3" id="hd_h_ch10.appf.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab2_1_1_1_3" id="hd_h_ch10.appf.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_h_ch10.appf.tab2_1_1_2_3 hd_h_ch10.appf.tab2_1_1_2_4 hd_h_ch10.appf.tab2_1_1_2_5 hd_h_ch10.appf.tab2_1_1_2_6 hd_h_ch10.appf.tab2_1_1_2_7 hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_h_ch10.appf.tab2_1_1_2_9 hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_h_ch10.appf.tab2_1_1_2_11 hd_h_ch10.appf.tab2_1_1_1_4 hd_h_ch10.appf.tab2_1_1_1_5" id="hd_b_ch10.appf.tab2_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref5" rid="ch10.s1.1.ref5">El Rafaey 1995</a>)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_3 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_4 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_5 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_6 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Noserious imprecision</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_7 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_9 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_11 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.7 lower (2.03 lower to 0.63 higher)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_4 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HIGH</td><td headers="hd_h_ch10.appf.tab2_1_1_1_5 hd_b_ch10.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_h_ch10.appf.tab2_1_1_2_3 hd_h_ch10.appf.tab2_1_1_2_4 hd_h_ch10.appf.tab2_1_1_2_5 hd_h_ch10.appf.tab2_1_1_2_6 hd_h_ch10.appf.tab2_1_1_2_7 hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_h_ch10.appf.tab2_1_1_2_9 hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_h_ch10.appf.tab2_1_1_2_11 hd_h_ch10.appf.tab2_1_1_1_4 hd_h_ch10.appf.tab2_1_1_1_5" id="hd_b_ch10.appf.tab2_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Complete abortion without the need for surgical intervention (follow-up mean 48 hours)</th></tr><tr><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref5" rid="ch10.s1.1.ref5">El Rafaey 1995</a>)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_3 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_4 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_5 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_6 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>2</sup></td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_7 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>34/35</p>
|
|
<p>(97.1%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_9 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>33/34</p>
|
|
<p>(97.1%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1 (0.92 to 1.09)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_11 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 fewer per 1000 (from 78 fewer to 87 more)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_4 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab2_1_1_1_5 hd_b_ch10.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_h_ch10.appf.tab2_1_1_2_3 hd_h_ch10.appf.tab2_1_1_2_4 hd_h_ch10.appf.tab2_1_1_2_5 hd_h_ch10.appf.tab2_1_1_2_6 hd_h_ch10.appf.tab2_1_1_2_7 hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_h_ch10.appf.tab2_1_1_2_9 hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_h_ch10.appf.tab2_1_1_2_11 hd_h_ch10.appf.tab2_1_1_1_4 hd_h_ch10.appf.tab2_1_1_1_5" id="hd_b_ch10.appf.tab2_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Incomplete abortion with the need for surgical intervention</th></tr><tr><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref5" rid="ch10.s1.1.ref5">El Rafaey 1995</a>)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_3 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_4 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_5 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_6 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_7 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1/34</p>
|
|
<p>(2.9%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_9 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/35</p>
|
|
<p>(0%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 3.09 (0.13 to 73.21)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_11 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable</td><td headers="hd_h_ch10.appf.tab2_1_1_1_4 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab2_1_1_1_5 hd_b_ch10.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_h_ch10.appf.tab2_1_1_2_3 hd_h_ch10.appf.tab2_1_1_2_4 hd_h_ch10.appf.tab2_1_1_2_5 hd_h_ch10.appf.tab2_1_1_2_6 hd_h_ch10.appf.tab2_1_1_2_7 hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_h_ch10.appf.tab2_1_1_2_9 hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_h_ch10.appf.tab2_1_1_2_11 hd_h_ch10.appf.tab2_1_1_1_4 hd_h_ch10.appf.tab2_1_1_1_5" id="hd_b_ch10.appf.tab2_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Haemorrhage requiring transfusion or >500 ml of blood loss</th></tr><tr><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref5" rid="ch10.s1.1.ref5">El Rafaey 1995</a>)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_3 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_4 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_5 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_6 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_7 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/35</p>
|
|
<p>(0%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_9 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/34</p>
|
|
<p>(0%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_11 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable</td><td headers="hd_h_ch10.appf.tab2_1_1_1_4 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab2_1_1_1_5 hd_b_ch10.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_h_ch10.appf.tab2_1_1_2_3 hd_h_ch10.appf.tab2_1_1_2_4 hd_h_ch10.appf.tab2_1_1_2_5 hd_h_ch10.appf.tab2_1_1_2_6 hd_h_ch10.appf.tab2_1_1_2_7 hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_h_ch10.appf.tab2_1_1_2_9 hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_h_ch10.appf.tab2_1_1_2_11 hd_h_ch10.appf.tab2_1_1_1_4 hd_h_ch10.appf.tab2_1_1_1_5" id="hd_b_ch10.appf.tab2_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Vomiting</th></tr><tr><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref5" rid="ch10.s1.1.ref5">El Rafaey 1995</a>)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_3 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_4 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_5 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_6 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_7 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>20/35</p>
|
|
<p>(57.1%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_9 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>21/34</p>
|
|
<p>(61.8%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.93 (0.63 to 1.37)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_11 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43 fewer per 1000 (from 229 fewer to 229 more)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_4 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab2_1_1_1_5 hd_b_ch10.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_h_ch10.appf.tab2_1_1_2_3 hd_h_ch10.appf.tab2_1_1_2_4 hd_h_ch10.appf.tab2_1_1_2_5 hd_h_ch10.appf.tab2_1_1_2_6 hd_h_ch10.appf.tab2_1_1_2_7 hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_h_ch10.appf.tab2_1_1_2_9 hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_h_ch10.appf.tab2_1_1_2_11 hd_h_ch10.appf.tab2_1_1_1_4 hd_h_ch10.appf.tab2_1_1_1_5" id="hd_b_ch10.appf.tab2_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Diarrhoea</th></tr><tr><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_1 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref5" rid="ch10.s1.1.ref5">El Rafaey 1995</a>)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_2 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_3 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_4 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_5 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_6 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab2_1_1_1_1 hd_h_ch10.appf.tab2_1_1_2_7 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_8 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10/35</p>
|
|
<p>(28.6%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_2 hd_h_ch10.appf.tab2_1_1_2_9 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>12/34</p>
|
|
<p>(35.3%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_10 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.81 (0.4 to 1.62)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_3 hd_h_ch10.appf.tab2_1_1_2_11 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67 fewer per 1000 (from 212 fewer to 219 more)</td><td headers="hd_h_ch10.appf.tab2_1_1_1_4 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab2_1_1_1_5 hd_b_ch10.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MD: mean difference; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab2_1"><p class="no_margin">MID boundaries −2.18, 0.78 (−0.7 +/− 2.95 * 0.5); clinically important effect = 2.95*0.5 = 1.48 higher or lower)</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab2_2"><p class="no_margin">The MID for this outcome is 3%, and the imprecision ratings were undertaken on that basis by using the absolute effect estimates so that if the CI crosses 30 fewer (3% of 1000) or 30 more, then the quality was downgraded by 1 level. If the CI crosses both, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab2_3"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab2_4"><p class="no_margin">The MID for this outcome is statistical significance, and the imprecision ratings were undertaken on that basis by using the optimum information size so that if the total event rate ≥300, then the quality was not downgraded, if the event rate = 150-299, then the quality was downgraded by 1 level and if the event rate <150, then the quality was downgraded by 2 levels</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab3"><div id="ch10.appf.tab3" class="table"><h3><span class="label">Table 5</span><span class="title">Clinical evidence profile: Comparison 3. Vaginal versus oral misoprostol (400 mcg; at 4 hour intervals for vaginal misoprostol and 3 hour intervals for oral misoprostol, up to 5 doses following a loading dose of vaginal misoprostol 800 mcg) 24 to 48 hours after oral mifepristone 200 mg</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab3_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab3_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab3_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab3_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab3_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab3_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab3_1_1_1_1" id="hd_h_ch10.appf.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab3_1_1_1_1" id="hd_h_ch10.appf.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab3_1_1_1_1" id="hd_h_ch10.appf.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab3_1_1_1_1" id="hd_h_ch10.appf.tab3_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab3_1_1_1_1" id="hd_h_ch10.appf.tab3_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab3_1_1_1_1" id="hd_h_ch10.appf.tab3_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab3_1_1_1_1" id="hd_h_ch10.appf.tab3_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab3_1_1_1_2" id="hd_h_ch10.appf.tab3_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vaginal misoprostol 400 mcg</th><th headers="hd_h_ch10.appf.tab3_1_1_1_2" id="hd_h_ch10.appf.tab3_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral misoprostol 400 mcg</th><th headers="hd_h_ch10.appf.tab3_1_1_1_3" id="hd_h_ch10.appf.tab3_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab3_1_1_1_3" id="hd_h_ch10.appf.tab3_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_1 hd_h_ch10.appf.tab3_1_1_2_2 hd_h_ch10.appf.tab3_1_1_2_3 hd_h_ch10.appf.tab3_1_1_2_4 hd_h_ch10.appf.tab3_1_1_2_5 hd_h_ch10.appf.tab3_1_1_2_6 hd_h_ch10.appf.tab3_1_1_2_7 hd_h_ch10.appf.tab3_1_1_1_2 hd_h_ch10.appf.tab3_1_1_2_8 hd_h_ch10.appf.tab3_1_1_2_9 hd_h_ch10.appf.tab3_1_1_1_3 hd_h_ch10.appf.tab3_1_1_2_10 hd_h_ch10.appf.tab3_1_1_2_11 hd_h_ch10.appf.tab3_1_1_1_4 hd_h_ch10.appf.tab3_1_1_1_5" id="hd_b_ch10.appf.tab3_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_1 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref4" rid="ch10.s1.1.ref4">Dickinson 2014</a>)</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_2 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_3 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_4 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_5 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_6 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_7 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab3_1_1_1_2 hd_h_ch10.appf.tab3_1_1_2_8 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 7.4 (6.5 to 8.2; n=100)</td><td headers="hd_h_ch10.appf.tab3_1_1_1_2 hd_h_ch10.appf.tab3_1_1_2_9 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 9.5 (8.5 to 11.4; n=100)</td><td headers="hd_h_ch10.appf.tab3_1_1_1_3 hd_h_ch10.appf.tab3_1_1_2_10 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab3_1_1_1_3 hd_h_ch10.appf.tab3_1_1_2_11 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab3_1_1_1_4 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERAT</td><td headers="hd_h_ch10.appf.tab3_1_1_1_5 hd_b_ch10.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_1 hd_h_ch10.appf.tab3_1_1_2_2 hd_h_ch10.appf.tab3_1_1_2_3 hd_h_ch10.appf.tab3_1_1_2_4 hd_h_ch10.appf.tab3_1_1_2_5 hd_h_ch10.appf.tab3_1_1_2_6 hd_h_ch10.appf.tab3_1_1_2_7 hd_h_ch10.appf.tab3_1_1_1_2 hd_h_ch10.appf.tab3_1_1_2_8 hd_h_ch10.appf.tab3_1_1_2_9 hd_h_ch10.appf.tab3_1_1_1_3 hd_h_ch10.appf.tab3_1_1_2_10 hd_h_ch10.appf.tab3_1_1_2_11 hd_h_ch10.appf.tab3_1_1_1_4 hd_h_ch10.appf.tab3_1_1_1_5" id="hd_b_ch10.appf.tab3_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Haemorrhage requiring transfusion or >500 ml of blood loss</th></tr><tr><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_1 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref4" rid="ch10.s1.1.ref4">Dickinson 2014</a>)</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_2 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_3 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_4 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_5 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_6 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_7 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab3_1_1_1_2 hd_h_ch10.appf.tab3_1_1_2_8 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1/100</p>
|
|
<p>(1%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab3_1_1_1_2 hd_h_ch10.appf.tab3_1_1_2_9 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2/100</p>
|
|
<p>(2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab3_1_1_1_3 hd_h_ch10.appf.tab3_1_1_2_10 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.5 (0.05 to 5.43)</td><td headers="hd_h_ch10.appf.tab3_1_1_1_3 hd_h_ch10.appf.tab3_1_1_2_11 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 fewer per 1000 (from 19 fewer to 89 more)</td><td headers="hd_h_ch10.appf.tab3_1_1_1_4 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab3_1_1_1_5 hd_b_ch10.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_1 hd_h_ch10.appf.tab3_1_1_2_2 hd_h_ch10.appf.tab3_1_1_2_3 hd_h_ch10.appf.tab3_1_1_2_4 hd_h_ch10.appf.tab3_1_1_2_5 hd_h_ch10.appf.tab3_1_1_2_6 hd_h_ch10.appf.tab3_1_1_2_7 hd_h_ch10.appf.tab3_1_1_1_2 hd_h_ch10.appf.tab3_1_1_2_8 hd_h_ch10.appf.tab3_1_1_2_9 hd_h_ch10.appf.tab3_1_1_1_3 hd_h_ch10.appf.tab3_1_1_2_10 hd_h_ch10.appf.tab3_1_1_2_11 hd_h_ch10.appf.tab3_1_1_1_4 hd_h_ch10.appf.tab3_1_1_1_5" id="hd_b_ch10.appf.tab3_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Patient satisfaction (opinion of procedure score; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_1 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref4" rid="ch10.s1.1.ref4">Dickinson 2014</a>)</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_2 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_3 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_4 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_5 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_6 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab3_1_1_1_1 hd_h_ch10.appf.tab3_1_1_2_7 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab3_1_1_1_2 hd_h_ch10.appf.tab3_1_1_2_8 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 50 (26 to 50; n=100)</td><td headers="hd_h_ch10.appf.tab3_1_1_1_2 hd_h_ch10.appf.tab3_1_1_2_9 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 50 (20 to 50; n=100)</td><td headers="hd_h_ch10.appf.tab3_1_1_1_3 hd_h_ch10.appf.tab3_1_1_2_10 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>5</sup></td><td headers="hd_h_ch10.appf.tab3_1_1_1_3 hd_h_ch10.appf.tab3_1_1_2_11 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>5</sup></td><td headers="hd_h_ch10.appf.tab3_1_1_1_4 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab3_1_1_1_5 hd_b_ch10.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab3_1"><p class="no_margin">As this outcome is only reported as medians and ranges for which there are no established or default GRADE MIDs, the imprecision ratings were undertaken by using the optimum information size so that if the total n≥400, then the quality was not downgraded, if n=200-399, then the quality was downgraded by 1 level and if the total n<200, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab3_2"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (hours), not means and standard deviations, which were: Vaginal misoprostol: Median (range) 7.4 (6.5 to 8.2; n=100); Oral misoprostol: Median (range) 9.5 (8.5 to 11.4; n=100); p < 0.05 (log rank test)</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab3_3"><p class="no_margin">The MID for this outcome is statistical significance, and the imprecision ratings were undertaken on that basis by using the optimum information size so that if the total event rate ≥300, then the quality was not downgraded, if the event rate = 150-299, then the quality was downgraded by 1 level and if the event rate <150, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab3_4"><p class="no_margin">The quality of evidence was downgraded by 1 level due to serious risk of bias because of lack of blinding for this subjective outcome</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch10.appf.tab3_5"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (opinion of procedure score), not means and standard deviations, which were: Vaginal misoprostol: Median (range) 50 (26 to 50; n=100); Oral misoprostol: Median (range) 50 (20 to 50; n=100); not significant</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab4"><div id="ch10.appf.tab4" class="table"><h3><span class="label">Table 6</span><span class="title">Clinical evidence profile: Comparison 4. Vaginal versus oral misoprostol (200 mcg; at 3 hour intervals, up to 5 doses) ± placebo 36 to 48 hours after 200 mg oral mifepristone</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab4_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab4_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab4_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab4_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab4_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab4_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab4_1_1_1_1" id="hd_h_ch10.appf.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab4_1_1_1_1" id="hd_h_ch10.appf.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab4_1_1_1_1" id="hd_h_ch10.appf.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab4_1_1_1_1" id="hd_h_ch10.appf.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab4_1_1_1_1" id="hd_h_ch10.appf.tab4_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab4_1_1_1_1" id="hd_h_ch10.appf.tab4_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab4_1_1_1_1" id="hd_h_ch10.appf.tab4_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab4_1_1_1_2" id="hd_h_ch10.appf.tab4_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vaginal misoprostol</th><th headers="hd_h_ch10.appf.tab4_1_1_1_2" id="hd_h_ch10.appf.tab4_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral misoprostol</th><th headers="hd_h_ch10.appf.tab4_1_1_1_3" id="hd_h_ch10.appf.tab4_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab4_1_1_1_3" id="hd_h_ch10.appf.tab4_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_1 hd_h_ch10.appf.tab4_1_1_2_2 hd_h_ch10.appf.tab4_1_1_2_3 hd_h_ch10.appf.tab4_1_1_2_4 hd_h_ch10.appf.tab4_1_1_2_5 hd_h_ch10.appf.tab4_1_1_2_6 hd_h_ch10.appf.tab4_1_1_2_7 hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_8 hd_h_ch10.appf.tab4_1_1_2_9 hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_10 hd_h_ch10.appf.tab4_1_1_2_11 hd_h_ch10.appf.tab4_1_1_1_4 hd_h_ch10.appf.tab4_1_1_1_5" id="hd_b_ch10.appf.tab4_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_1 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref7" rid="ch10.s1.1.ref7">Ho 1997</a>)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_2 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_3 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_4 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_5 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_6 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_7 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_8 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49</td><td headers="hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_9 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49</td><td headers="hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_10 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_11 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 13 lower (23.23 to 2.77 lower)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_4 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab4_1_1_1_5 hd_b_ch10.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_1 hd_h_ch10.appf.tab4_1_1_2_2 hd_h_ch10.appf.tab4_1_1_2_3 hd_h_ch10.appf.tab4_1_1_2_4 hd_h_ch10.appf.tab4_1_1_2_5 hd_h_ch10.appf.tab4_1_1_2_6 hd_h_ch10.appf.tab4_1_1_2_7 hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_8 hd_h_ch10.appf.tab4_1_1_2_9 hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_10 hd_h_ch10.appf.tab4_1_1_2_11 hd_h_ch10.appf.tab4_1_1_1_4 hd_h_ch10.appf.tab4_1_1_1_5" id="hd_b_ch10.appf.tab4_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Complete abortion without the need for surgical intervention (follow-up mean 48 hours)</th></tr><tr><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_1 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref7" rid="ch10.s1.1.ref7">Ho 1997</a>)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_2 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_3 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_4 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_5 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_6 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>2</sup></td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_7 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_8 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>36/49</p>
|
|
<p>(73.5%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_9 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>29/49</p>
|
|
<p>(59.2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_10 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.24 (0.93 to 1.65)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_11 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">142 more per 1000 (from 41 fewer to 385 more)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_4 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab4_1_1_1_5 hd_b_ch10.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_1 hd_h_ch10.appf.tab4_1_1_2_2 hd_h_ch10.appf.tab4_1_1_2_3 hd_h_ch10.appf.tab4_1_1_2_4 hd_h_ch10.appf.tab4_1_1_2_5 hd_h_ch10.appf.tab4_1_1_2_6 hd_h_ch10.appf.tab4_1_1_2_7 hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_8 hd_h_ch10.appf.tab4_1_1_2_9 hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_10 hd_h_ch10.appf.tab4_1_1_2_11 hd_h_ch10.appf.tab4_1_1_1_4 hd_h_ch10.appf.tab4_1_1_1_5" id="hd_b_ch10.appf.tab4_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Vomiting</th></tr><tr><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_1 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref7" rid="ch10.s1.1.ref7">Ho 1997</a>)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_2 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_3 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_4 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_5 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_6 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_7 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_8 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>14/49</p>
|
|
<p>(28.6%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_9 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10/49</p>
|
|
<p>(20.4%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_10 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.4 (0.69 to 2.84)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_11 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82 more per 1000 (from 63 fewer to 376 more)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_4 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab4_1_1_1_5 hd_b_ch10.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_1 hd_h_ch10.appf.tab4_1_1_2_2 hd_h_ch10.appf.tab4_1_1_2_3 hd_h_ch10.appf.tab4_1_1_2_4 hd_h_ch10.appf.tab4_1_1_2_5 hd_h_ch10.appf.tab4_1_1_2_6 hd_h_ch10.appf.tab4_1_1_2_7 hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_8 hd_h_ch10.appf.tab4_1_1_2_9 hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_10 hd_h_ch10.appf.tab4_1_1_2_11 hd_h_ch10.appf.tab4_1_1_1_4 hd_h_ch10.appf.tab4_1_1_1_5" id="hd_b_ch10.appf.tab4_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Diarrhoea</th></tr><tr><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_1 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref7" rid="ch10.s1.1.ref7">Ho 1997</a>)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_2 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_3 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_4 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_5 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_6 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab4_1_1_1_1 hd_h_ch10.appf.tab4_1_1_2_7 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_8 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>9/49</p>
|
|
<p>(18.4%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab4_1_1_1_2 hd_h_ch10.appf.tab4_1_1_2_9 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>16/49</p>
|
|
<p>(32.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_10 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.56 (0.28 to 1.15)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_3 hd_h_ch10.appf.tab4_1_1_2_11 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">144 fewer per 1000 (from 235 fewer to 49 more)</td><td headers="hd_h_ch10.appf.tab4_1_1_1_4 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab4_1_1_1_5 hd_b_ch10.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MD: mean difference; MID: minimally important difference; RR: risk ratio; SD: standard deviation</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab4_1"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MID (MID boundaries −22.1,−3.9(−13 +/− 18.2 * 0.5); clinically important effect = 18.2*0.5 = 9.1 higher or lower)</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab4_2"><p class="no_margin">The MID for this outcome is 3%, and the imprecision ratings were undertaken on that basis by using the absolute effect estimates so that if the CI crosses 30 fewer (3% of 1000) or 30 more, then the quality was downgraded by 1 level. If the CI crosses both, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab4_3"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab4_4"><p class="no_margin">The quality of evidence was downgraded by 1 level as the 95% confidence interval crosses 1 MID</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab5"><div id="ch10.appf.tab5" class="table"><h3><span class="label">Table 7</span><span class="title">Clinical evidence profile: Comparison 5. Oral versus vaginal misoprostol (400 mcg at 3 hour intervals, up to 5 doses) ± placebo 36 to 48 hours after oral mifepristone 200 mg</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab5_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab5_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab5_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab5_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab5_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab5_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab5_1_1_1_1" id="hd_h_ch10.appf.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab5_1_1_1_1" id="hd_h_ch10.appf.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab5_1_1_1_1" id="hd_h_ch10.appf.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab5_1_1_1_1" id="hd_h_ch10.appf.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab5_1_1_1_1" id="hd_h_ch10.appf.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab5_1_1_1_1" id="hd_h_ch10.appf.tab5_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab5_1_1_1_1" id="hd_h_ch10.appf.tab5_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab5_1_1_1_2" id="hd_h_ch10.appf.tab5_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral misoprostol</th><th headers="hd_h_ch10.appf.tab5_1_1_1_2" id="hd_h_ch10.appf.tab5_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vaginal misoprostol</th><th headers="hd_h_ch10.appf.tab5_1_1_1_3" id="hd_h_ch10.appf.tab5_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab5_1_1_1_3" id="hd_h_ch10.appf.tab5_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_h_ch10.appf.tab5_1_1_2_3 hd_h_ch10.appf.tab5_1_1_2_4 hd_h_ch10.appf.tab5_1_1_2_5 hd_h_ch10.appf.tab5_1_1_2_6 hd_h_ch10.appf.tab5_1_1_2_7 hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_h_ch10.appf.tab5_1_1_2_9 hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_h_ch10.appf.tab5_1_1_2_11 hd_h_ch10.appf.tab5_1_1_1_4 hd_h_ch10.appf.tab5_1_1_1_5" id="hd_b_ch10.appf.tab5_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref10" rid="ch10.s1.1.ref10">Ngai 2000</a>)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_3 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_4 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_5 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_6 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious imprecision<sup>2</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_7 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_9 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_11 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 1.3 lower (8.7 lower to 11.33 higher)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_4 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab5_1_1_1_5 hd_b_ch10.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_h_ch10.appf.tab5_1_1_2_3 hd_h_ch10.appf.tab5_1_1_2_4 hd_h_ch10.appf.tab5_1_1_2_5 hd_h_ch10.appf.tab5_1_1_2_6 hd_h_ch10.appf.tab5_1_1_2_7 hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_h_ch10.appf.tab5_1_1_2_9 hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_h_ch10.appf.tab5_1_1_2_11 hd_h_ch10.appf.tab5_1_1_1_4 hd_h_ch10.appf.tab5_1_1_1_5" id="hd_b_ch10.appf.tab5_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Complete abortion without the need for surgical intervention (follow-up mean 48 hours)</th></tr><tr><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref10" rid="ch10.s1.1.ref10">Ngai 2000</a>)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_3 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_4 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_5 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_6 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_7 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>57/70</p>
|
|
<p>(81.4%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_9 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>58/69</p>
|
|
<p>(84.1%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.97 (0.83 to 1.13)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_11 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25 fewer per 1000 (from 143 fewer to 109 more)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_4 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab5_1_1_1_5 hd_b_ch10.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_h_ch10.appf.tab5_1_1_2_3 hd_h_ch10.appf.tab5_1_1_2_4 hd_h_ch10.appf.tab5_1_1_2_5 hd_h_ch10.appf.tab5_1_1_2_6 hd_h_ch10.appf.tab5_1_1_2_7 hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_h_ch10.appf.tab5_1_1_2_9 hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_h_ch10.appf.tab5_1_1_2_11 hd_h_ch10.appf.tab5_1_1_1_4 hd_h_ch10.appf.tab5_1_1_1_5" id="hd_b_ch10.appf.tab5_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Incomplete abortion with the need for surgical intervention</th></tr><tr><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref10" rid="ch10.s1.1.ref10">Ngai 2000</a>)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_3 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_4 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_5 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_6 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_7 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/70</p>
|
|
<p>(0%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_9 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/69</p>
|
|
<p>(0%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_11 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable</td><td headers="hd_h_ch10.appf.tab5_1_1_1_4 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab5_1_1_1_5 hd_b_ch10.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_h_ch10.appf.tab5_1_1_2_3 hd_h_ch10.appf.tab5_1_1_2_4 hd_h_ch10.appf.tab5_1_1_2_5 hd_h_ch10.appf.tab5_1_1_2_6 hd_h_ch10.appf.tab5_1_1_2_7 hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_h_ch10.appf.tab5_1_1_2_9 hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_h_ch10.appf.tab5_1_1_2_11 hd_h_ch10.appf.tab5_1_1_1_4 hd_h_ch10.appf.tab5_1_1_1_5" id="hd_b_ch10.appf.tab5_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Vomiting</th></tr><tr><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref10" rid="ch10.s1.1.ref10">Ngai 2000</a>)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_3 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_4 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_5 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_6 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>5</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_7 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>31/70</p>
|
|
<p>(44.3%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_9 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>29/69</p>
|
|
<p>(42%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.05 (0.72 to 1.54)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_11 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21 more per 1000 (from 118 fewer to 227 more)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_4 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab5_1_1_1_5 hd_b_ch10.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_h_ch10.appf.tab5_1_1_2_3 hd_h_ch10.appf.tab5_1_1_2_4 hd_h_ch10.appf.tab5_1_1_2_5 hd_h_ch10.appf.tab5_1_1_2_6 hd_h_ch10.appf.tab5_1_1_2_7 hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_h_ch10.appf.tab5_1_1_2_9 hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_h_ch10.appf.tab5_1_1_2_11 hd_h_ch10.appf.tab5_1_1_1_4 hd_h_ch10.appf.tab5_1_1_1_5" id="hd_b_ch10.appf.tab5_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Diarrhoea</th></tr><tr><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_1 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref10" rid="ch10.s1.1.ref10">Ngai 2000</a>)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_2 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_3 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_4 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_5 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_6 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>6</sup></td><td headers="hd_h_ch10.appf.tab5_1_1_1_1 hd_h_ch10.appf.tab5_1_1_2_7 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_8 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>28/70</p>
|
|
<p>(40%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab5_1_1_1_2 hd_h_ch10.appf.tab5_1_1_2_9 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>16/69</p>
|
|
<p>(23.2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_10 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.73 (1.03 to 2.89)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_3 hd_h_ch10.appf.tab5_1_1_2_11 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">169 more per 1000 (from 7 more to 438 more)</td><td headers="hd_h_ch10.appf.tab5_1_1_1_4 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab5_1_1_1_5 hd_b_ch10.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MD: mean difference; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab5_1"><p class="no_margin">The quality of evidence was downgraded by 1 level due to serious risk of bias arising from unclear method of randomization</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab5_2"><p class="no_margin">MID boundaries (−18.45, 15.85(−1.3 +/− 34.3 * 0.5); clinically important effect = 34.3*0.5 = 17.15 higher or lower)</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab5_3"><p class="no_margin">The MID for this outcome is 3%, and the imprecision ratings were undertaken on that basis by using the absolute effect estimates so that if the CI crosses 30 fewer (3% of 1000) or 30 more, then the quality was downgraded by 1 level. If the CI crosses both, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab5_4"><p class="no_margin">The quality of evidence was downgraded by 2 levels due to very serious imprecision because of small number of events</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch10.appf.tab5_5"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="ch10.appf.tab5_6"><p class="no_margin">The quality of evidence was downgraded by 1 level as the 95% confidence interval crosses 1 MID</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab6"><div id="ch10.appf.tab6" class="table"><h3><span class="label">Table 8</span><span class="title">Clinical evidence profile: Comparison 6. Sublingual versus oral misoprostol (400 mcg; at 3 hour intervals, up to 5 doses following a loading dose of vaginal misoprostol 800 mcg) 24 to 48 hours after oral mifepristone 200 mg</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab6_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab6_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab6_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab6_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab6_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab6_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab6_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab6_1_1_1_1" id="hd_h_ch10.appf.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab6_1_1_1_1" id="hd_h_ch10.appf.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab6_1_1_1_1" id="hd_h_ch10.appf.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab6_1_1_1_1" id="hd_h_ch10.appf.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab6_1_1_1_1" id="hd_h_ch10.appf.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab6_1_1_1_1" id="hd_h_ch10.appf.tab6_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab6_1_1_1_1" id="hd_h_ch10.appf.tab6_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab6_1_1_1_2" id="hd_h_ch10.appf.tab6_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sublingual misoprostol</th><th headers="hd_h_ch10.appf.tab6_1_1_1_2" id="hd_h_ch10.appf.tab6_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral misoprostol</th><th headers="hd_h_ch10.appf.tab6_1_1_1_3" id="hd_h_ch10.appf.tab6_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab6_1_1_1_3" id="hd_h_ch10.appf.tab6_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_1 hd_h_ch10.appf.tab6_1_1_2_2 hd_h_ch10.appf.tab6_1_1_2_3 hd_h_ch10.appf.tab6_1_1_2_4 hd_h_ch10.appf.tab6_1_1_2_5 hd_h_ch10.appf.tab6_1_1_2_6 hd_h_ch10.appf.tab6_1_1_2_7 hd_h_ch10.appf.tab6_1_1_1_2 hd_h_ch10.appf.tab6_1_1_2_8 hd_h_ch10.appf.tab6_1_1_2_9 hd_h_ch10.appf.tab6_1_1_1_3 hd_h_ch10.appf.tab6_1_1_2_10 hd_h_ch10.appf.tab6_1_1_2_11 hd_h_ch10.appf.tab6_1_1_1_4 hd_h_ch10.appf.tab6_1_1_1_5" id="hd_b_ch10.appf.tab6_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_1 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref4" rid="ch10.s1.1.ref4">Dickinson 2014</a>)</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_2 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_3 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_4 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_5 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_6 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_7 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab6_1_1_1_2 hd_h_ch10.appf.tab6_1_1_2_8 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 7.8 (7 to 9.2 n=102)</td><td headers="hd_h_ch10.appf.tab6_1_1_1_2 hd_h_ch10.appf.tab6_1_1_2_9 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 9.5 (8.5 to 11.4; n=100)</td><td headers="hd_h_ch10.appf.tab6_1_1_1_3 hd_h_ch10.appf.tab6_1_1_2_10 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab6_1_1_1_3 hd_h_ch10.appf.tab6_1_1_2_11 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab6_1_1_1_4 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab6_1_1_1_5 hd_b_ch10.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_1 hd_h_ch10.appf.tab6_1_1_2_2 hd_h_ch10.appf.tab6_1_1_2_3 hd_h_ch10.appf.tab6_1_1_2_4 hd_h_ch10.appf.tab6_1_1_2_5 hd_h_ch10.appf.tab6_1_1_2_6 hd_h_ch10.appf.tab6_1_1_2_7 hd_h_ch10.appf.tab6_1_1_1_2 hd_h_ch10.appf.tab6_1_1_2_8 hd_h_ch10.appf.tab6_1_1_2_9 hd_h_ch10.appf.tab6_1_1_1_3 hd_h_ch10.appf.tab6_1_1_2_10 hd_h_ch10.appf.tab6_1_1_2_11 hd_h_ch10.appf.tab6_1_1_1_4 hd_h_ch10.appf.tab6_1_1_1_5" id="hd_b_ch10.appf.tab6_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Haemorrhage requiring transfusion or >500 ml of blood loss</th></tr><tr><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_1 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref4" rid="ch10.s1.1.ref4">Dickinson 2014</a>)</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_2 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_3 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_4 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_5 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_6 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_7 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab6_1_1_1_2 hd_h_ch10.appf.tab6_1_1_2_8 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2/102</p>
|
|
<p>(2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab6_1_1_1_2 hd_h_ch10.appf.tab6_1_1_2_9 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2/100</p>
|
|
<p>(2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab6_1_1_1_3 hd_h_ch10.appf.tab6_1_1_2_10 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.98 (0.14 to 6.83)</td><td headers="hd_h_ch10.appf.tab6_1_1_1_3 hd_h_ch10.appf.tab6_1_1_2_11 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 fewer per 1000 (from 17 fewer to 117 more)</td><td headers="hd_h_ch10.appf.tab6_1_1_1_4 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab6_1_1_1_5 hd_b_ch10.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_1 hd_h_ch10.appf.tab6_1_1_2_2 hd_h_ch10.appf.tab6_1_1_2_3 hd_h_ch10.appf.tab6_1_1_2_4 hd_h_ch10.appf.tab6_1_1_2_5 hd_h_ch10.appf.tab6_1_1_2_6 hd_h_ch10.appf.tab6_1_1_2_7 hd_h_ch10.appf.tab6_1_1_1_2 hd_h_ch10.appf.tab6_1_1_2_8 hd_h_ch10.appf.tab6_1_1_2_9 hd_h_ch10.appf.tab6_1_1_1_3 hd_h_ch10.appf.tab6_1_1_2_10 hd_h_ch10.appf.tab6_1_1_2_11 hd_h_ch10.appf.tab6_1_1_1_4 hd_h_ch10.appf.tab6_1_1_1_5" id="hd_b_ch10.appf.tab6_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Patient satisfaction (opinion of procedure score; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_1 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref4" rid="ch10.s1.1.ref4">Dickinson 2014</a>)</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_2 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_3 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_4 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_5 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_6 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab6_1_1_1_1 hd_h_ch10.appf.tab6_1_1_2_7 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab6_1_1_1_2 hd_h_ch10.appf.tab6_1_1_2_8 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 50 (19-50; n=102)</td><td headers="hd_h_ch10.appf.tab6_1_1_1_2 hd_h_ch10.appf.tab6_1_1_2_9 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 50 (20-50; n=100)</td><td headers="hd_h_ch10.appf.tab6_1_1_1_3 hd_h_ch10.appf.tab6_1_1_2_10 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>5</sup></td><td headers="hd_h_ch10.appf.tab6_1_1_1_3 hd_h_ch10.appf.tab6_1_1_2_11 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>5</sup></td><td headers="hd_h_ch10.appf.tab6_1_1_1_4 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab6_1_1_1_5 hd_b_ch10.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab6_1"><p class="no_margin">As this outcome is only reported as medians and ranges for which there are no established or default GRADE MIDs, the imprecision ratings were undertaken by using the optimum information size so that if the total n≥400, then the quality was not downgraded, if n=200-399, then the quality was downgraded by 1 level and if the total n<200, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab6_2"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (hours), not means and standard deviations, which were: Sublingual misoprostol: Median (range) 7.8 (7 to 9.2; n=102); Oral misoprostol: Median (range) 9.5 (8.5 to 11.4; n=100); p < 0.05 (log rank test)</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab6_3"><p class="no_margin">The MID for this outcome is statistical significance, and the imprecision ratings were undertaken on that basis by using the optimum information size so that if the total event rate ≥300, then the quality was not downgraded, if the event rate = 150-299, then the quality was downgraded by 1 level and if the event rate <150, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab6_4"><p class="no_margin">The quality of evidence was downgraded by 1 level due to serious risk of bias because of lack of blinding for this subjective outcome</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch10.appf.tab6_5"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (opinion of procedure scores), not means and standard deviations, which were: Sublingual misoprostol: Median (range) 50 (19 to 50; n=102); Oral misoprostol: Median (range) 50 (20 to 50; n=100); not significant</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab7"><div id="ch10.appf.tab7" class="table"><h3><span class="label">Table 9</span><span class="title">Clinical evidence profile: Comparison 7. Sublingual versus oral misoprostol (400 mcg, at 3 hour intervals up to 5 doses) 36 to 48 hours after oral mifepristone 200 mg</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab7_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab7_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab7_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab7_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab7_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab7_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab7_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab7_1_1_1_1" id="hd_h_ch10.appf.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab7_1_1_1_1" id="hd_h_ch10.appf.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab7_1_1_1_1" id="hd_h_ch10.appf.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab7_1_1_1_1" id="hd_h_ch10.appf.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab7_1_1_1_1" id="hd_h_ch10.appf.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab7_1_1_1_1" id="hd_h_ch10.appf.tab7_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab7_1_1_1_1" id="hd_h_ch10.appf.tab7_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab7_1_1_1_2" id="hd_h_ch10.appf.tab7_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sublingual misoprostol</th><th headers="hd_h_ch10.appf.tab7_1_1_1_2" id="hd_h_ch10.appf.tab7_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral misoprostol</th><th headers="hd_h_ch10.appf.tab7_1_1_1_3" id="hd_h_ch10.appf.tab7_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab7_1_1_1_3" id="hd_h_ch10.appf.tab7_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_1 hd_h_ch10.appf.tab7_1_1_2_2 hd_h_ch10.appf.tab7_1_1_2_3 hd_h_ch10.appf.tab7_1_1_2_4 hd_h_ch10.appf.tab7_1_1_2_5 hd_h_ch10.appf.tab7_1_1_2_6 hd_h_ch10.appf.tab7_1_1_2_7 hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_8 hd_h_ch10.appf.tab7_1_1_2_9 hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_10 hd_h_ch10.appf.tab7_1_1_2_11 hd_h_ch10.appf.tab7_1_1_1_4 hd_h_ch10.appf.tab7_1_1_1_5" id="hd_b_ch10.appf.tab7_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_1 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref12" rid="ch10.s1.1.ref12">Tang 2005</a>)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_2 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_3 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_4 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_5 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_6 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_7 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_8 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 5.5 (1.4 to 43.2; n=58)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_9 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 7.5 (2.4 to 38.8; n=60)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_10 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_11 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab7_1_1_1_4 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab7_1_1_1_5 hd_b_ch10.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_1 hd_h_ch10.appf.tab7_1_1_2_2 hd_h_ch10.appf.tab7_1_1_2_3 hd_h_ch10.appf.tab7_1_1_2_4 hd_h_ch10.appf.tab7_1_1_2_5 hd_h_ch10.appf.tab7_1_1_2_6 hd_h_ch10.appf.tab7_1_1_2_7 hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_8 hd_h_ch10.appf.tab7_1_1_2_9 hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_10 hd_h_ch10.appf.tab7_1_1_2_11 hd_h_ch10.appf.tab7_1_1_1_4 hd_h_ch10.appf.tab7_1_1_1_5" id="hd_b_ch10.appf.tab7_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Complete abortion without the need for surgical intervention (follow-up mean 48 hours)</th></tr><tr><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_1 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref12" rid="ch10.s1.1.ref12">Tang 2005</a>)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_2 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_3 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_4 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_5 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_6 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_7 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_8 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>57/58</p>
|
|
<p>(98.3%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_9 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>55/60</p>
|
|
<p>(91.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_10 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.07 (0.99 to 1.17)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_11 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64 more per 1000 (from 9 fewer to 156 more)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_4 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab7_1_1_1_5 hd_b_ch10.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_1 hd_h_ch10.appf.tab7_1_1_2_2 hd_h_ch10.appf.tab7_1_1_2_3 hd_h_ch10.appf.tab7_1_1_2_4 hd_h_ch10.appf.tab7_1_1_2_5 hd_h_ch10.appf.tab7_1_1_2_6 hd_h_ch10.appf.tab7_1_1_2_7 hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_8 hd_h_ch10.appf.tab7_1_1_2_9 hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_10 hd_h_ch10.appf.tab7_1_1_2_11 hd_h_ch10.appf.tab7_1_1_1_4 hd_h_ch10.appf.tab7_1_1_1_5" id="hd_b_ch10.appf.tab7_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Incomplete abortion with the need for surgical intervention</th></tr><tr><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_1 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref12" rid="ch10.s1.1.ref12">Tang 2005</a>)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_2 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_3 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_4 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_5 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_6 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_7 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_8 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10/58</p>
|
|
<p>(17.2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_9 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7/60</p>
|
|
<p>(11.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_10 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.48 (0.6 to 3.62)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_11 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56 more per 1000 (from 47 fewer to 306 more)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_4 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab7_1_1_1_5 hd_b_ch10.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_1 hd_h_ch10.appf.tab7_1_1_2_2 hd_h_ch10.appf.tab7_1_1_2_3 hd_h_ch10.appf.tab7_1_1_2_4 hd_h_ch10.appf.tab7_1_1_2_5 hd_h_ch10.appf.tab7_1_1_2_6 hd_h_ch10.appf.tab7_1_1_2_7 hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_8 hd_h_ch10.appf.tab7_1_1_2_9 hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_10 hd_h_ch10.appf.tab7_1_1_2_11 hd_h_ch10.appf.tab7_1_1_1_4 hd_h_ch10.appf.tab7_1_1_1_5" id="hd_b_ch10.appf.tab7_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Diarrhoea</th></tr><tr><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_1 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref12" rid="ch10.s1.1.ref12">Tang 2005</a>)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_2 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_3 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_4 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_5 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_6 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab7_1_1_1_1 hd_h_ch10.appf.tab7_1_1_2_7 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_8 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>8/58</p>
|
|
<p>(13.8%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab7_1_1_1_2 hd_h_ch10.appf.tab7_1_1_2_9 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>13/60</p>
|
|
<p>(21.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_10 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.64 (0.29 to 1.42)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_3 hd_h_ch10.appf.tab7_1_1_2_11 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78 fewer per 1000 (from 154 fewer to 91 more)</td><td headers="hd_h_ch10.appf.tab7_1_1_1_4 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab7_1_1_1_5 hd_b_ch10.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab7_1"><p class="no_margin">As this outcome is only reported as medians and ranges for which there are no established or default GRADE MIDs, the imprecision ratings were undertaken by using the optimum information size so that if the total n≥400, then the quality was not downgraded, if n=200-399, then the quality was downgraded by 1 level and if the total n<200, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab7_2"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (hours), not means and standard deviations, which were: Sublingual misoprostol: Median (range) 5.5(1.4 to 43.2; n=58); Oral misoprostol: Median (range) 7.5 (2.4 to 38.8; n=100); p < 0.05 (Mann-Whitney U-Test)</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab7_3"><p class="no_margin">The MID for this outcome is 3%, and the imprecision ratings were undertaken on that basis by using the absolute effect estimates so that if the CI crosses 30 fewer (3% of 1000) or 30 more, then the quality was downgraded by 1 level. If the CI crosses both, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab7_4"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab8"><div id="ch10.appf.tab8" class="table"><h3><span class="label">Table 10</span><span class="title">Clinical evidence profile: Comparison 8. Sublingual (600 mcg; followed by 400 mcg at 3 hour intervals up to 5 doses) versus vaginal (800 mcg; followed by 400 mcg at 3 hour intervals up to 5 doses) misoprostol, 36 to 48 hours after oral mifepristone 200 mg</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab8_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab8_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab8_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab8_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab8_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab8_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab8_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab8_1_1_1_1" id="hd_h_ch10.appf.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab8_1_1_1_1" id="hd_h_ch10.appf.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab8_1_1_1_1" id="hd_h_ch10.appf.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab8_1_1_1_1" id="hd_h_ch10.appf.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab8_1_1_1_1" id="hd_h_ch10.appf.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab8_1_1_1_1" id="hd_h_ch10.appf.tab8_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab8_1_1_1_1" id="hd_h_ch10.appf.tab8_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab8_1_1_1_2" id="hd_h_ch10.appf.tab8_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sublingual misoprostol</th><th headers="hd_h_ch10.appf.tab8_1_1_1_2" id="hd_h_ch10.appf.tab8_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vaginal misoprostol</th><th headers="hd_h_ch10.appf.tab8_1_1_1_3" id="hd_h_ch10.appf.tab8_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab8_1_1_1_3" id="hd_h_ch10.appf.tab8_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_h_ch10.appf.tab8_1_1_2_3 hd_h_ch10.appf.tab8_1_1_2_4 hd_h_ch10.appf.tab8_1_1_2_5 hd_h_ch10.appf.tab8_1_1_2_6 hd_h_ch10.appf.tab8_1_1_2_7 hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_h_ch10.appf.tab8_1_1_2_9 hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_h_ch10.appf.tab8_1_1_2_11 hd_h_ch10.appf.tab8_1_1_1_4 hd_h_ch10.appf.tab8_1_1_1_5" id="hd_b_ch10.appf.tab8_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref6" rid="ch10.s1.1.ref6">Hamoda 2005</a>)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_3 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_4 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_5 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_6 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_7 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 5.27 (0.55 to 29.35; n=36)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_9 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 5.40 (2.10 to 13.00; n=40)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_11 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab8_1_1_1_4 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab8_1_1_1_5 hd_b_ch10.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_h_ch10.appf.tab8_1_1_2_3 hd_h_ch10.appf.tab8_1_1_2_4 hd_h_ch10.appf.tab8_1_1_2_5 hd_h_ch10.appf.tab8_1_1_2_6 hd_h_ch10.appf.tab8_1_1_2_7 hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_h_ch10.appf.tab8_1_1_2_9 hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_h_ch10.appf.tab8_1_1_2_11 hd_h_ch10.appf.tab8_1_1_1_4 hd_h_ch10.appf.tab8_1_1_1_5" id="hd_b_ch10.appf.tab8_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Incomplete abortion with the need for surgical intervention</th></tr><tr><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref6" rid="ch10.s1.1.ref6">Hamoda 2005</a>)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_3 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_4 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_5 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_6 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_7 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3/36</p>
|
|
<p>(8.3%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_9 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1/40</p>
|
|
<p>(2.5%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 3.33 (0.36 to 30.63)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_11 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58 more per 1000 (from 16 fewer to 741 more)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_4 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab8_1_1_1_5 hd_b_ch10.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_h_ch10.appf.tab8_1_1_2_3 hd_h_ch10.appf.tab8_1_1_2_4 hd_h_ch10.appf.tab8_1_1_2_5 hd_h_ch10.appf.tab8_1_1_2_6 hd_h_ch10.appf.tab8_1_1_2_7 hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_h_ch10.appf.tab8_1_1_2_9 hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_h_ch10.appf.tab8_1_1_2_11 hd_h_ch10.appf.tab8_1_1_1_4 hd_h_ch10.appf.tab8_1_1_1_5" id="hd_b_ch10.appf.tab8_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Vomiting</th></tr><tr><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref6" rid="ch10.s1.1.ref6">Hamoda 2005</a>)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_3 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_4 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_5 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_6 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_7 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>25/36</p>
|
|
<p>(69.4%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_9 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>25/40</p>
|
|
<p>(62.5%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.11 (0.80 to 1.54)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_11 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69 more per 1000 (from 125 fewer to 337 more)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_4 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab8_1_1_1_5 hd_b_ch10.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_h_ch10.appf.tab8_1_1_2_3 hd_h_ch10.appf.tab8_1_1_2_4 hd_h_ch10.appf.tab8_1_1_2_5 hd_h_ch10.appf.tab8_1_1_2_6 hd_h_ch10.appf.tab8_1_1_2_7 hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_h_ch10.appf.tab8_1_1_2_9 hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_h_ch10.appf.tab8_1_1_2_11 hd_h_ch10.appf.tab8_1_1_1_4 hd_h_ch10.appf.tab8_1_1_1_5" id="hd_b_ch10.appf.tab8_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Satisfaction (satisfied with the route of administration of misoprostol)</th></tr><tr><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref6" rid="ch10.s1.1.ref6">Hamoda 2005</a>)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_3 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_4 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_5 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_6 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_7 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>24/36</p>
|
|
<p>(66.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_9 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>25/40</p>
|
|
<p>(62.5%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.07 (0.76 to 1.49)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_11 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44 more per 1000 (from 150 fewer to 306 more)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_4 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab8_1_1_1_5 hd_b_ch10.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_h_ch10.appf.tab8_1_1_2_3 hd_h_ch10.appf.tab8_1_1_2_4 hd_h_ch10.appf.tab8_1_1_2_5 hd_h_ch10.appf.tab8_1_1_2_6 hd_h_ch10.appf.tab8_1_1_2_7 hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_h_ch10.appf.tab8_1_1_2_9 hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_h_ch10.appf.tab8_1_1_2_11 hd_h_ch10.appf.tab8_1_1_1_4 hd_h_ch10.appf.tab8_1_1_1_5" id="hd_b_ch10.appf.tab8_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Diarrhoea</th></tr><tr><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_1 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref6" rid="ch10.s1.1.ref6">Hamoda 2005</a>)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_2 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_3 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_4 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_5 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_6 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab8_1_1_1_1 hd_h_ch10.appf.tab8_1_1_2_7 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_8 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>19/36</p>
|
|
<p>(52.8%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab8_1_1_1_2 hd_h_ch10.appf.tab8_1_1_2_9 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>21/40</p>
|
|
<p>(52.5%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_10 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.01 (0.66 to 1.54)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_3 hd_h_ch10.appf.tab8_1_1_2_11 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 more per 1000 (from 178 fewer to 283 more)</td><td headers="hd_h_ch10.appf.tab8_1_1_1_4 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab8_1_1_1_5 hd_b_ch10.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab8_1"><p class="no_margin">As this outcome is only reported as medians and ranges for which there are no established or default GRADE MIDs, the imprecision ratings were undertaken by using the optimum information size so that if the total n≥400, then the quality was not downgraded, if n=200-399, then the quality was downgraded by 1 level and if the total n<200, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab8_2"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (hours), not means and standard deviations, which were: Sublingual misoprostol: Median (range) 5.27(0.55 to 29.35; n=36); Vaginal misoprostol: Median (range) 5.40 (2.10 to 13.00; n=40); not significant (Mann-Whitney U-Test)</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab8_3"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab8_4"><p class="no_margin">The quality of evidence was downgraded by 1 level due to serious risk of bias because of lack of blinding for this subjective outcome</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab9"><div id="ch10.appf.tab9" class="table"><h3><span class="label">Table 11</span><span class="title">Clinical evidence profile: Comparison 9. Oral misoprostol (400 mcg; every 6 hours, up to 2 doses) 1 versus 2 days after oral mifepristone 200 mg + 600 mcg vaginal misoprostol</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab9_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab9_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab9_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab9_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab9_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab9_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab9_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab9_1_1_1_1" id="hd_h_ch10.appf.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab9_1_1_1_1" id="hd_h_ch10.appf.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab9_1_1_1_1" id="hd_h_ch10.appf.tab9_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab9_1_1_1_1" id="hd_h_ch10.appf.tab9_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab9_1_1_1_1" id="hd_h_ch10.appf.tab9_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab9_1_1_1_1" id="hd_h_ch10.appf.tab9_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab9_1_1_1_1" id="hd_h_ch10.appf.tab9_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab9_1_1_1_2" id="hd_h_ch10.appf.tab9_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 day interval</th><th headers="hd_h_ch10.appf.tab9_1_1_1_2" id="hd_h_ch10.appf.tab9_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 day interval</th><th headers="hd_h_ch10.appf.tab9_1_1_1_3" id="hd_h_ch10.appf.tab9_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab9_1_1_1_3" id="hd_h_ch10.appf.tab9_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_h_ch10.appf.tab9_1_1_2_3 hd_h_ch10.appf.tab9_1_1_2_4 hd_h_ch10.appf.tab9_1_1_2_5 hd_h_ch10.appf.tab9_1_1_2_6 hd_h_ch10.appf.tab9_1_1_2_7 hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_h_ch10.appf.tab9_1_1_2_9 hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_h_ch10.appf.tab9_1_1_2_11 hd_h_ch10.appf.tab9_1_1_1_4 hd_h_ch10.appf.tab9_1_1_1_5" id="hd_b_ch10.appf.tab9_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref8" rid="ch10.s1.1.ref8">Hou 2010</a>)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_3 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_4 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_5 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_6 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious imprecision<sup>2</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_7 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_9 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_11 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD 0.20 (1.25 lower to 1.65 higher)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_4 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab9_1_1_1_5 hd_b_ch10.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_h_ch10.appf.tab9_1_1_2_3 hd_h_ch10.appf.tab9_1_1_2_4 hd_h_ch10.appf.tab9_1_1_2_5 hd_h_ch10.appf.tab9_1_1_2_6 hd_h_ch10.appf.tab9_1_1_2_7 hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_h_ch10.appf.tab9_1_1_2_9 hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_h_ch10.appf.tab9_1_1_2_11 hd_h_ch10.appf.tab9_1_1_1_4 hd_h_ch10.appf.tab9_1_1_1_5" id="hd_b_ch10.appf.tab9_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Complete abortion without the need for surgical intervention (follow-up mean 24 hours)</th></tr><tr><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref8" rid="ch10.s1.1.ref8">Hou 2010</a>)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_3 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_4 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_5 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_6 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_7 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>23/50</p>
|
|
<p>(46%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_9 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>34/50</p>
|
|
<p>(68%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.68 (0.47 to 0.97)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_11 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 fewer per 1000 (from 20 fewer to 360 fewer)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_4 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab9_1_1_1_5 hd_b_ch10.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_h_ch10.appf.tab9_1_1_2_3 hd_h_ch10.appf.tab9_1_1_2_4 hd_h_ch10.appf.tab9_1_1_2_5 hd_h_ch10.appf.tab9_1_1_2_6 hd_h_ch10.appf.tab9_1_1_2_7 hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_h_ch10.appf.tab9_1_1_2_9 hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_h_ch10.appf.tab9_1_1_2_11 hd_h_ch10.appf.tab9_1_1_1_4 hd_h_ch10.appf.tab9_1_1_1_5" id="hd_b_ch10.appf.tab9_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Incomplete abortion with the need for surgical intervention</th></tr><tr><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref8" rid="ch10.s1.1.ref8">Hou 2010</a>)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_3 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_4 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_5 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_6 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_7 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1/50</p>
|
|
<p>(2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_9 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/50</p>
|
|
<p>(0%)</p>
|
|
<p>0%</p>
|
|
</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 3.00 (0.13 to 71.92)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_11 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable</td><td headers="hd_h_ch10.appf.tab9_1_1_1_4 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab9_1_1_1_5 hd_b_ch10.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_h_ch10.appf.tab9_1_1_2_3 hd_h_ch10.appf.tab9_1_1_2_4 hd_h_ch10.appf.tab9_1_1_2_5 hd_h_ch10.appf.tab9_1_1_2_6 hd_h_ch10.appf.tab9_1_1_2_7 hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_h_ch10.appf.tab9_1_1_2_9 hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_h_ch10.appf.tab9_1_1_2_11 hd_h_ch10.appf.tab9_1_1_1_4 hd_h_ch10.appf.tab9_1_1_1_5" id="hd_b_ch10.appf.tab9_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Vomiting (Nausea/Vomiting)</th></tr><tr><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref8" rid="ch10.s1.1.ref8">Hou 2010</a>)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_3 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>5</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_4 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_5 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>6</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_6 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_7 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>14/50</p>
|
|
<p>(28%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_9 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>15/50</p>
|
|
<p>(30%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.93 (0.51 to 1.72)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_11 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21 fewer per 1000 (from 147 fewer to 216 more)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_4 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab9_1_1_1_5 hd_b_ch10.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_h_ch10.appf.tab9_1_1_2_3 hd_h_ch10.appf.tab9_1_1_2_4 hd_h_ch10.appf.tab9_1_1_2_5 hd_h_ch10.appf.tab9_1_1_2_6 hd_h_ch10.appf.tab9_1_1_2_7 hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_h_ch10.appf.tab9_1_1_2_9 hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_h_ch10.appf.tab9_1_1_2_11 hd_h_ch10.appf.tab9_1_1_1_4 hd_h_ch10.appf.tab9_1_1_1_5" id="hd_b_ch10.appf.tab9_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Diarrhoea</th></tr><tr><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_1 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref8" rid="ch10.s1.1.ref8">Hou 2010</a>)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_2 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_3 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>5</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_4 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_5 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_6 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab9_1_1_1_1 hd_h_ch10.appf.tab9_1_1_2_7 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_8 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>9/50</p>
|
|
<p>(18%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab9_1_1_1_2 hd_h_ch10.appf.tab9_1_1_2_9 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4/50</p>
|
|
<p>(8%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_10 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 2.25 (0.74 to 6.83)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_3 hd_h_ch10.appf.tab9_1_1_2_11 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100 more per 1000 (from 21 fewer to 466 more)</td><td headers="hd_h_ch10.appf.tab9_1_1_1_4 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab9_1_1_1_5 hd_b_ch10.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MD: mean difference; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab9_1"><p class="no_margin">The quality of evidence was downgraded by 1 level due to serious risk of bias arising from unclear allocation concealment method</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab9_2"><p class="no_margin">MID boundaries (−1.3, 1.7(0.2 +/− 3 * 0.5); clinically important effect = 3*0.5 = 1.5 higher or lower))</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab9_3"><p class="no_margin">The MID for this outcome is 3%, and the imprecision ratings were undertaken on that basis by using the absolute effect estimates so that if the CI crosses 30 fewer (3% of 1000) or 30 more, then the quality was downgraded by 1 level. If the CI crosses both, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab9_4"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch10.appf.tab9_5"><p class="no_margin">The quality of evidence was downgraded by 2 levels due to very serious risk of bias from unclear allocation concealment method and attrition bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="ch10.appf.tab9_6"><p class="no_margin">The quality of evidence was downgraded by 1 level due to indirectness of outcome reported as all cases of nausea and vomiting, instead of vomiting alone</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab10"><div id="ch10.appf.tab10" class="table"><h3><span class="label">Table 12</span><span class="title">Clinical evidence profile: Comparison 10. Vaginal misoprostol (400 mcg; at 3 hour intervals, up to 5 doses per 24 hours) 1 versus 2 days after oral mifepristone 200 mg</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab10_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab10_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab10_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab10_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab10_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab10_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab10_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab10_1_1_1_1" id="hd_h_ch10.appf.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab10_1_1_1_1" id="hd_h_ch10.appf.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab10_1_1_1_1" id="hd_h_ch10.appf.tab10_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab10_1_1_1_1" id="hd_h_ch10.appf.tab10_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab10_1_1_1_1" id="hd_h_ch10.appf.tab10_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab10_1_1_1_1" id="hd_h_ch10.appf.tab10_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab10_1_1_1_1" id="hd_h_ch10.appf.tab10_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab10_1_1_1_2" id="hd_h_ch10.appf.tab10_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 day interval</th><th headers="hd_h_ch10.appf.tab10_1_1_1_2" id="hd_h_ch10.appf.tab10_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 day interval</th><th headers="hd_h_ch10.appf.tab10_1_1_1_3" id="hd_h_ch10.appf.tab10_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab10_1_1_1_3" id="hd_h_ch10.appf.tab10_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_1 hd_h_ch10.appf.tab10_1_1_2_2 hd_h_ch10.appf.tab10_1_1_2_3 hd_h_ch10.appf.tab10_1_1_2_4 hd_h_ch10.appf.tab10_1_1_2_5 hd_h_ch10.appf.tab10_1_1_2_6 hd_h_ch10.appf.tab10_1_1_2_7 hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_8 hd_h_ch10.appf.tab10_1_1_2_9 hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_10 hd_h_ch10.appf.tab10_1_1_2_11 hd_h_ch10.appf.tab10_1_1_1_4 hd_h_ch10.appf.tab10_1_1_1_5" id="hd_b_ch10.appf.tab10_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_1 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref9" rid="ch10.s1.1.ref9">Mentula 2011</a>)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_2 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_3 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_4 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_5 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_6 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_7 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_8 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 8.5 (6.3 to 12.3; n=115)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_9 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 7.2 (5.8 to 9.2; n=112)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_10 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_11 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab10_1_1_1_4 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab10_1_1_1_5 hd_b_ch10.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_1 hd_h_ch10.appf.tab10_1_1_2_2 hd_h_ch10.appf.tab10_1_1_2_3 hd_h_ch10.appf.tab10_1_1_2_4 hd_h_ch10.appf.tab10_1_1_2_5 hd_h_ch10.appf.tab10_1_1_2_6 hd_h_ch10.appf.tab10_1_1_2_7 hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_8 hd_h_ch10.appf.tab10_1_1_2_9 hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_10 hd_h_ch10.appf.tab10_1_1_2_11 hd_h_ch10.appf.tab10_1_1_1_4 hd_h_ch10.appf.tab10_1_1_1_5" id="hd_b_ch10.appf.tab10_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Incomplete abortion with the need for surgical intervention</th></tr><tr><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_1 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref9" rid="ch10.s1.1.ref9">Mentula 2011</a>)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_2 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_3 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_4 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_5 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_6 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_7 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_8 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>29/115</p>
|
|
<p>(25.2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_9 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>41/112</p>
|
|
<p>(36.6%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_10 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.69 (0.46 to 1.03)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_11 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">113 fewer per 1000 (from 198 fewer to 11 more)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_4 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab10_1_1_1_5 hd_b_ch10.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_1 hd_h_ch10.appf.tab10_1_1_2_2 hd_h_ch10.appf.tab10_1_1_2_3 hd_h_ch10.appf.tab10_1_1_2_4 hd_h_ch10.appf.tab10_1_1_2_5 hd_h_ch10.appf.tab10_1_1_2_6 hd_h_ch10.appf.tab10_1_1_2_7 hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_8 hd_h_ch10.appf.tab10_1_1_2_9 hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_10 hd_h_ch10.appf.tab10_1_1_2_11 hd_h_ch10.appf.tab10_1_1_1_4 hd_h_ch10.appf.tab10_1_1_1_5" id="hd_b_ch10.appf.tab10_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Haemorrhage requiring transfusion or >500 ml of blood loss</th></tr><tr><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_1 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref9" rid="ch10.s1.1.ref9">Mentula 2011</a>)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_2 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_3 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_4 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_5 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_6 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_7 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_8 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>8/115</p>
|
|
<p>(7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_9 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7/112</p>
|
|
<p>(6.3%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_10 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.11 (0.42 to 2.97)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_11 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 more per 1000 (from 36 fewer to 123 more)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_4 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab10_1_1_1_5 hd_b_ch10.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_1 hd_h_ch10.appf.tab10_1_1_2_2 hd_h_ch10.appf.tab10_1_1_2_3 hd_h_ch10.appf.tab10_1_1_2_4 hd_h_ch10.appf.tab10_1_1_2_5 hd_h_ch10.appf.tab10_1_1_2_6 hd_h_ch10.appf.tab10_1_1_2_7 hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_8 hd_h_ch10.appf.tab10_1_1_2_9 hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_10 hd_h_ch10.appf.tab10_1_1_2_11 hd_h_ch10.appf.tab10_1_1_1_4 hd_h_ch10.appf.tab10_1_1_1_5" id="hd_b_ch10.appf.tab10_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Vomiting (The need for anti-emetic drugs)</th></tr><tr><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_1 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref9" rid="ch10.s1.1.ref9">Mentula 2011</a>)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_2 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_3 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_4 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_5 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>5</sup></td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_6 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>6</sup></td><td headers="hd_h_ch10.appf.tab10_1_1_1_1 hd_h_ch10.appf.tab10_1_1_2_7 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_8 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>30/115</p>
|
|
<p>(26.1%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab10_1_1_1_2 hd_h_ch10.appf.tab10_1_1_2_9 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>24/112</p>
|
|
<p>(21.4%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_10 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.22 (0.76 to 1.95)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_3 hd_h_ch10.appf.tab10_1_1_2_11 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47 more per 1000 (from 51 fewer to 204 more)</td><td headers="hd_h_ch10.appf.tab10_1_1_1_4 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab10_1_1_1_5 hd_b_ch10.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab10_1"><p class="no_margin">As this outcome is only reported as medians and ranges for which there are no established or default GRADE MIDs, the imprecision ratings were undertaken by using the optimum information size so that if the total n≥400, then the quality was not downgraded, if n=200-399, then the quality was downgraded by 1 level and if the total n<200, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab10_2"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (hours), not means and standard deviations, which were: 1 day interval: Median (range) 8.5 (6.3 to 12.3; n=115); 2 day interval: Median (range)= 7.2 (5.8 to 9.2; n=112); p<0.05 (Mann-Whitney U-Test)</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab10_3"><p class="no_margin">The quality of evidence was downgraded by 1 level as the 95% confidence interval crosses 1 MID</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab10_4"><p class="no_margin">The MID for this outcome is statistical significance, and the imprecision ratings were undertaken on that basis by using the optimum information size so that if the total event rate ≥300, then the quality was not downgraded, if the event rate = 150-299, then the quality was downgraded by 1 level and if the event rate <150, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch10.appf.tab10_5"><p class="no_margin">The quality of evidence was downgraded by 1 level due to indirectness of outcome reported as women needing anti-emetic drugs instead of those experiencing vomiting</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="ch10.appf.tab10_6"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab11"><div id="ch10.appf.tab11" class="table"><h3><span class="label">Table 13</span><span class="title">Clinical evidence profile: Comparison 11. Vaginal misoprostol (600 mcg; followed by 400 mcg at 3 hour intervals, up to 4 doses) simultaneous with mifepristone 200 mg versus 36 to 38 hours after 200 mg oral mifepristone</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab11_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab11_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab11_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab11_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab11_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab11_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab11_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab11_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab11_1_1_1_1" id="hd_h_ch10.appf.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab11_1_1_1_1" id="hd_h_ch10.appf.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab11_1_1_1_1" id="hd_h_ch10.appf.tab11_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab11_1_1_1_1" id="hd_h_ch10.appf.tab11_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab11_1_1_1_1" id="hd_h_ch10.appf.tab11_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab11_1_1_1_1" id="hd_h_ch10.appf.tab11_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab11_1_1_1_1" id="hd_h_ch10.appf.tab11_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab11_1_1_1_2" id="hd_h_ch10.appf.tab11_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Simultaneous administration</th><th headers="hd_h_ch10.appf.tab11_1_1_1_2" id="hd_h_ch10.appf.tab11_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36 to 38 hours interval</th><th headers="hd_h_ch10.appf.tab11_1_1_1_3" id="hd_h_ch10.appf.tab11_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab11_1_1_1_3" id="hd_h_ch10.appf.tab11_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_h_ch10.appf.tab11_1_1_2_3 hd_h_ch10.appf.tab11_1_1_2_4 hd_h_ch10.appf.tab11_1_1_2_5 hd_h_ch10.appf.tab11_1_1_2_6 hd_h_ch10.appf.tab11_1_1_2_7 hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_h_ch10.appf.tab11_1_1_2_9 hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_h_ch10.appf.tab11_1_1_2_11 hd_h_ch10.appf.tab11_1_1_1_4 hd_h_ch10.appf.tab11_1_1_1_5" id="hd_b_ch10.appf.tab11_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref3" rid="ch10.s1.1.ref3">Chai 2009</a>)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_3 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_4 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_5 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_6 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_7 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 10.0 (3.5 to 126; n=71)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_9 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 4.9 (1.8 to 13.8; n=70)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_11 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>2</sup></td><td headers="hd_h_ch10.appf.tab11_1_1_1_4 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab11_1_1_1_5 hd_b_ch10.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_h_ch10.appf.tab11_1_1_2_3 hd_h_ch10.appf.tab11_1_1_2_4 hd_h_ch10.appf.tab11_1_1_2_5 hd_h_ch10.appf.tab11_1_1_2_6 hd_h_ch10.appf.tab11_1_1_2_7 hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_h_ch10.appf.tab11_1_1_2_9 hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_h_ch10.appf.tab11_1_1_2_11 hd_h_ch10.appf.tab11_1_1_1_4 hd_h_ch10.appf.tab11_1_1_1_5" id="hd_b_ch10.appf.tab11_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Complete abortion without the need for surgical intervention (follow-up mean 48 hours)</th></tr><tr><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref3" rid="ch10.s1.1.ref3">Chai 2009</a>)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_3 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_4 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_5 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_6 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_7 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>70/71</p>
|
|
<p>(98.6%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_9 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>70/70</p>
|
|
<p>(100%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.99 (0.95 to 1.03)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_11 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 fewer per 1000 (from 50 fewer to 30 more)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_4 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab11_1_1_1_5 hd_b_ch10.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_h_ch10.appf.tab11_1_1_2_3 hd_h_ch10.appf.tab11_1_1_2_4 hd_h_ch10.appf.tab11_1_1_2_5 hd_h_ch10.appf.tab11_1_1_2_6 hd_h_ch10.appf.tab11_1_1_2_7 hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_h_ch10.appf.tab11_1_1_2_9 hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_h_ch10.appf.tab11_1_1_2_11 hd_h_ch10.appf.tab11_1_1_1_4 hd_h_ch10.appf.tab11_1_1_1_5" id="hd_b_ch10.appf.tab11_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Incomplete abortion with the need for surgical intervention</th></tr><tr><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref3" rid="ch10.s1.1.ref3">Chai 2009</a>)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_3 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_4 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_5 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_6 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_7 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5/71</p>
|
|
<p>(7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_9 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1/70</p>
|
|
<p>(1.4%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 4.93 (0.59 to 41.13)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_11 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56 more per 1000 (from 6 fewer to 573 more)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_4 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab11_1_1_1_5 hd_b_ch10.appf.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_h_ch10.appf.tab11_1_1_2_3 hd_h_ch10.appf.tab11_1_1_2_4 hd_h_ch10.appf.tab11_1_1_2_5 hd_h_ch10.appf.tab11_1_1_2_6 hd_h_ch10.appf.tab11_1_1_2_7 hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_h_ch10.appf.tab11_1_1_2_9 hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_h_ch10.appf.tab11_1_1_2_11 hd_h_ch10.appf.tab11_1_1_1_4 hd_h_ch10.appf.tab11_1_1_1_5" id="hd_b_ch10.appf.tab11_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Haemorrhage requiring transfusion or >500 ml of blood loss</th></tr><tr><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref3" rid="ch10.s1.1.ref3">Chai 2009</a>)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_3 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_4 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_5 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_6 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>5</sup></td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_7 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/71</p>
|
|
<p>(0%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_9 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/70</p>
|
|
<p>(0%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable</td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_11 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable</td><td headers="hd_h_ch10.appf.tab11_1_1_1_4 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab11_1_1_1_5 hd_b_ch10.appf.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_h_ch10.appf.tab11_1_1_2_3 hd_h_ch10.appf.tab11_1_1_2_4 hd_h_ch10.appf.tab11_1_1_2_5 hd_h_ch10.appf.tab11_1_1_2_6 hd_h_ch10.appf.tab11_1_1_2_7 hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_h_ch10.appf.tab11_1_1_2_9 hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_h_ch10.appf.tab11_1_1_2_11 hd_h_ch10.appf.tab11_1_1_1_4 hd_h_ch10.appf.tab11_1_1_1_5" id="hd_b_ch10.appf.tab11_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Diarrhoea (>3 episodes)</th></tr><tr><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_1 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref3" rid="ch10.s1.1.ref3">Chai 2009</a>)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_2 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_3 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious risk of bias</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_4 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_5 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_6 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>6</sup></td><td headers="hd_h_ch10.appf.tab11_1_1_1_1 hd_h_ch10.appf.tab11_1_1_2_7 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_8 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>18/71</p>
|
|
<p>(25.4%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab11_1_1_1_2 hd_h_ch10.appf.tab11_1_1_2_9 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10/70</p>
|
|
<p>(14.3%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_10 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.77 (0.88 to 3.57)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_3 hd_h_ch10.appf.tab11_1_1_2_11 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110 more per 1000 (from 17 fewer to 367 more)</td><td headers="hd_h_ch10.appf.tab11_1_1_1_4 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab11_1_1_1_5 hd_b_ch10.appf.tab11_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab11_1"><p class="no_margin">As this outcome is only reported as medians and ranges for which there are no established or default GRADE MIDs, the imprecision ratings were undertaken by using the optimum information size so that if the total n≥400, then the quality was not downgraded, if n=200-399, then the quality was downgraded by 1 level and if the total n<200, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab11_2"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (hours), not means and standard deviations, which were: Simultaneous administration: Median (range) 10.0 (3.5 to 126; n=71); 36 to 38 hours interval: Median (range) 4.9 (1.8 to 13.8; n=70); p<0.0001 (Mann-Whitney U-Test)</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab11_3"><p class="no_margin">The MID for this outcome is 3%, and the imprecision ratings were undertaken on that basis by using the absolute effect estimates so that if the CI crosses 30 fewer (3% of 1000) or 30 more, then the quality was downgraded by 1 level. If the CI crosses both, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab11_4"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch10.appf.tab11_5"><p class="no_margin">The MID for this outcome is statistical significance, and the imprecision ratings were undertaken on that basis by using the optimum information size so that if the total event rate ≥300, then the quality was not downgraded, if the event rate = 150-299, then the quality was downgraded by 1 level and if the event rate <150, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="ch10.appf.tab11_6"><p class="no_margin">The quality of evidence was downgraded by 1 level as the 95% confidence interval crosses 1 MID</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appftab12"><div id="ch10.appf.tab12" class="table"><h3><span class="label">Table 14</span><span class="title">Clinical evidence profile: Comparison 12. Buccal misoprostol 400 mcg (at 3 hour intervals) ± placebo simultaneous with mifepristone 200 mg versus 1 day following oral mifepristone 200 mg</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appf.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appf.tab12_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch10.appf.tab12_1_1_1_1" colspan="7" rowspan="1" style="text-align:left;vertical-align:bottom;">Quality assessment</th><th id="hd_h_ch10.appf.tab12_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">No of patients</th><th id="hd_h_ch10.appf.tab12_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Effect</th><th id="hd_h_ch10.appf.tab12_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab12_1_1_1_4" style="text-align:left;vertical-align:bottom;">Quality</th><th id="hd_h_ch10.appf.tab12_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch10.appf.tab12_1_1_1_5" style="text-align:left;vertical-align:bottom;">Importance</th></tr><tr><th headers="hd_h_ch10.appf.tab12_1_1_1_1" id="hd_h_ch10.appf.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No of studies</th><th headers="hd_h_ch10.appf.tab12_1_1_1_1" id="hd_h_ch10.appf.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design</th><th headers="hd_h_ch10.appf.tab12_1_1_1_1" id="hd_h_ch10.appf.tab12_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</th><th headers="hd_h_ch10.appf.tab12_1_1_1_1" id="hd_h_ch10.appf.tab12_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</th><th headers="hd_h_ch10.appf.tab12_1_1_1_1" id="hd_h_ch10.appf.tab12_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</th><th headers="hd_h_ch10.appf.tab12_1_1_1_1" id="hd_h_ch10.appf.tab12_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</th><th headers="hd_h_ch10.appf.tab12_1_1_1_1" id="hd_h_ch10.appf.tab12_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other considerations</th><th headers="hd_h_ch10.appf.tab12_1_1_1_2" id="hd_h_ch10.appf.tab12_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Simultaneous administration</th><th headers="hd_h_ch10.appf.tab12_1_1_1_2" id="hd_h_ch10.appf.tab12_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 day interval</th><th headers="hd_h_ch10.appf.tab12_1_1_1_3" id="hd_h_ch10.appf.tab12_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relative (95% CI)</th><th headers="hd_h_ch10.appf.tab12_1_1_1_3" id="hd_h_ch10.appf.tab12_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_h_ch10.appf.tab12_1_1_2_3 hd_h_ch10.appf.tab12_1_1_2_4 hd_h_ch10.appf.tab12_1_1_2_5 hd_h_ch10.appf.tab12_1_1_2_6 hd_h_ch10.appf.tab12_1_1_2_7 hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_h_ch10.appf.tab12_1_1_2_9 hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_h_ch10.appf.tab12_1_1_2_11 hd_h_ch10.appf.tab12_1_1_1_4 hd_h_ch10.appf.tab12_1_1_1_5" id="hd_b_ch10.appf.tab12_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Time to expulsion (Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_3 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_4 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_5 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_6 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious imprecision<sup>2</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_7 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 13.0 (4.9 to 47.8; n=254)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_9 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median (range) 7.7 (2.1 to 40.3; n=251)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>3</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_11 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable<sup>3</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_4 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab12_1_1_1_5 hd_b_ch10.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_h_ch10.appf.tab12_1_1_2_3 hd_h_ch10.appf.tab12_1_1_2_4 hd_h_ch10.appf.tab12_1_1_2_5 hd_h_ch10.appf.tab12_1_1_2_6 hd_h_ch10.appf.tab12_1_1_2_7 hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_h_ch10.appf.tab12_1_1_2_9 hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_h_ch10.appf.tab12_1_1_2_11 hd_h_ch10.appf.tab12_1_1_1_4 hd_h_ch10.appf.tab12_1_1_1_5" id="hd_b_ch10.appf.tab12_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Complete abortion without the need for surgical intervention(at 48 hours)</th></tr><tr><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_3 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_4 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_5 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_6 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>4</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_7 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>243/254</p>
|
|
<p>(95.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_9 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>243/251</p>
|
|
<p>(96.8%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 0.99 (0.95 to 1.02)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_11 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 fewer per 1000 (from 48 fewer to 19 more)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_4 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LOW</td><td headers="hd_h_ch10.appf.tab12_1_1_1_5 hd_b_ch10.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_h_ch10.appf.tab12_1_1_2_3 hd_h_ch10.appf.tab12_1_1_2_4 hd_h_ch10.appf.tab12_1_1_2_5 hd_h_ch10.appf.tab12_1_1_2_6 hd_h_ch10.appf.tab12_1_1_2_7 hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_h_ch10.appf.tab12_1_1_2_9 hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_h_ch10.appf.tab12_1_1_2_11 hd_h_ch10.appf.tab12_1_1_1_4 hd_h_ch10.appf.tab12_1_1_1_5" id="hd_b_ch10.appf.tab12_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Incomplete abortion with the need for surgical intervention</th></tr><tr><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_3 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_4 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_5 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_6 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>5</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_7 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2/254</p>
|
|
<p>(0.79%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_9 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1/251</p>
|
|
<p>(0.4%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.98 (0.18 to 21.66)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_11 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 more per 1000 (from 3 fewer to 82 more)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_4 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab12_1_1_1_5 hd_b_ch10.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_h_ch10.appf.tab12_1_1_2_3 hd_h_ch10.appf.tab12_1_1_2_4 hd_h_ch10.appf.tab12_1_1_2_5 hd_h_ch10.appf.tab12_1_1_2_6 hd_h_ch10.appf.tab12_1_1_2_7 hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_h_ch10.appf.tab12_1_1_2_9 hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_h_ch10.appf.tab12_1_1_2_11 hd_h_ch10.appf.tab12_1_1_1_4 hd_h_ch10.appf.tab12_1_1_1_5" id="hd_b_ch10.appf.tab12_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Haemorrhage requiring transfusion or >500 ml of blood loss</th></tr><tr><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_3 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_4 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_5 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_6 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>6</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_7 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1/254</p>
|
|
<p>(0.39%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_9 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0/251</p>
|
|
<p>(0%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 2.96 (0.12 to 72.43)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_11 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not estimable</td><td headers="hd_h_ch10.appf.tab12_1_1_1_4 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab12_1_1_1_5 hd_b_ch10.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_h_ch10.appf.tab12_1_1_2_3 hd_h_ch10.appf.tab12_1_1_2_4 hd_h_ch10.appf.tab12_1_1_2_5 hd_h_ch10.appf.tab12_1_1_2_6 hd_h_ch10.appf.tab12_1_1_2_7 hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_h_ch10.appf.tab12_1_1_2_9 hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_h_ch10.appf.tab12_1_1_2_11 hd_h_ch10.appf.tab12_1_1_1_4 hd_h_ch10.appf.tab12_1_1_1_5" id="hd_b_ch10.appf.tab12_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Vomiting</th></tr><tr><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_3 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_4 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_5 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_6 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>5</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_7 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>63/254</p>
|
|
<p>(24.8%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_9 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>57/251</p>
|
|
<p>(22.7%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.09 (0.8 to 1.49)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_11 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 more per 1000 (from 45 fewer to 111 more)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_4 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VERY LOW</td><td headers="hd_h_ch10.appf.tab12_1_1_1_5 hd_b_ch10.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_h_ch10.appf.tab12_1_1_2_3 hd_h_ch10.appf.tab12_1_1_2_4 hd_h_ch10.appf.tab12_1_1_2_5 hd_h_ch10.appf.tab12_1_1_2_6 hd_h_ch10.appf.tab12_1_1_2_7 hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_h_ch10.appf.tab12_1_1_2_9 hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_h_ch10.appf.tab12_1_1_2_11 hd_h_ch10.appf.tab12_1_1_1_4 hd_h_ch10.appf.tab12_1_1_1_5" id="hd_b_ch10.appf.tab12_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Patient satisfaction (satisfied or very satisfied)</th></tr><tr><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_3 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_4 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_5 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_6 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious imprecision</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_7 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>252/254</p>
|
|
<p>(99.2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_9 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>249/251</p>
|
|
<p>(99.2%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1 (0.98 to 1.02)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_11 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 fewer per 1000 (from 20 fewer to 20 more)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_4 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab12_1_1_1_5 hd_b_ch10.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_h_ch10.appf.tab12_1_1_2_3 hd_h_ch10.appf.tab12_1_1_2_4 hd_h_ch10.appf.tab12_1_1_2_5 hd_h_ch10.appf.tab12_1_1_2_6 hd_h_ch10.appf.tab12_1_1_2_7 hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_h_ch10.appf.tab12_1_1_2_9 hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_h_ch10.appf.tab12_1_1_2_11 hd_h_ch10.appf.tab12_1_1_1_4 hd_h_ch10.appf.tab12_1_1_1_5" id="hd_b_ch10.appf.tab12_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Diarrhoea</th></tr><tr><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_1 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#ch10.s1.1.ref1" rid="ch10.s1.1.ref1">Abbas 2016</a>)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_2 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised trials</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_3 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_4 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious inconsistency</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_5 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious indirectness</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_6 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious imprecision</td><td headers="hd_h_ch10.appf.tab12_1_1_1_1 hd_h_ch10.appf.tab12_1_1_2_7 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_8 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>137/254</p>
|
|
<p>(53.9%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_2 hd_h_ch10.appf.tab12_1_1_2_9 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>83/251</p>
|
|
<p>(33.1%)</p>
|
|
</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_10 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RR 1.63 (1.32 to 2.01)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_3 hd_h_ch10.appf.tab12_1_1_2_11 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">208 more per 1000 (from 106 more to 334 more)</td><td headers="hd_h_ch10.appf.tab12_1_1_1_4 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MODERATE</td><td headers="hd_h_ch10.appf.tab12_1_1_1_5 hd_b_ch10.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CI: confidence interval; MID: minimally important difference; RR: risk ratio</p></div></dd></dl><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch10.appf.tab12_1"><p class="no_margin">The quality of evidence was downgraded by 2 levels due to serious risk of bias arising from unclear randomization methods</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch10.appf.tab12_2"><p class="no_margin">As this outcome is only reported as medians and ranges for which there are no established or default GRADE MIDs, the imprecision ratings were undertaken by using the optimum information size so that if the total n≥400, then the quality was not downgraded, if n=200-399, then the quality was downgraded by 1 level and if the total n<200, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch10.appf.tab12_3"><p class="no_margin">Cannot be rated/calculated as the study only reports medians and ranges (hours), not means and standard deviations, which were: Simultaneous administration: Median (range) 13.0 (4.9 to 47.8; n=254); 1 day interval: Median (range) 7.7 (2.1 to 40.3); n=251); p<0.001 (Mann-Whitney U-test)</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch10.appf.tab12_4"><p class="no_margin">The MID for this outcome is 3%, and the imprecision ratings were undertaken on that basis by using the absolute effect estimates so that if the CI crosses 30 fewer (3% of 1000) or 30 more, then the quality was downgraded by 1 level. If the CI crosses both, then the quality was downgraded by 2 levels</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch10.appf.tab12_5"><p class="no_margin">The quality of evidence was downgraded by 2 levels as the 95% confidence interval crosses 2 MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="ch10.appf.tab12_6"><p class="no_margin">The MID for this outcome is statistical significance, and the imprecision ratings were undertaken on that basis by using the optimum information size so that if the total event rate ≥300, then the quality was not downgraded, if the event rate = 150-299, then the quality was downgraded by 1 level and if the event rate <150, then the quality was downgraded by 2 levels</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch10appktab1"><div id="ch10.appk.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK561115/table/ch10.appk.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch10.appk.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reason for Exclusion</th></tr></thead><tbody><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Agrawal, S., Misoprostol for second trimester medical abortion - a comparison of three routes of administration, International journal of gynaecology and obstetrics, 107, 2009</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Al, R. A., Yapca, O. E., Vaginal misoprostol compared with buccal misoprostol for termination of second-trimester pregnancy, Obstetrics and gynecology, 126, 593-598, 2015</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Azra, B, Shakeel, S, Nilofer, M, A comparison of two protocols of intra vaginal misoprostol for second trimester medical termination of pregnancy, Pakistan armed forces medical journal, 57, 61-65, 2007</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bebbington,M.W., Kent,N., Lim,K., Gagnon,A., Delisle,M.F., Tessier,F., Wilson,R.D., A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination, American Journal of Obstetrics and Gynecology, 187, 853-857, 2002</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Behrashi, M., Mahdian, M., Vaginal versus oral misoprostol for second-trimester pregnancy termination: A randomized trial, Pakistan Journal of Biological Sciences, 11, 2505-2508, 2008</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bhattacharjee, N., Saha, S. P., Ganguly, R. P., Patra, K. K., Jha, T., Barui, G., Saha, M., A randomized comparative study on vaginal administration of acetic acid-moistened versus dry misoprostol for mid-trimester pregnancy termination, Archives of gynecology and obstetrics, 285, 311-316, 2012</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bhattacharjee, N., Saha, S. P., Ghoshroy, S. C., Bhowmik, S., Barui, G., A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks, Australian and New Zealand Journal of Obstetrics and Gynaecology, 48, 165-171, 2008</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bhattacharyya, S. K., Mukherji, J., Kamilya, G. S., Ray, S., Hazra, A., Two regimens of vaginal misoprostol in second trimester termination of pregnancy: a prospective randomised trial, Acta obstetricia ET gynecologica scandinavica, 85, 1458-62, 2006</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cabrera, Y., FernUndez-Guisasola, J., Lobo, P., G. Umir S, Ulvarez, J., Comparison of sublingual versus vaginal misoprostol for second-trimester pregnancy termination: A meta-analysis, Australian and New Zealand Journal of Obstetrics and Gynaecology, 51, 158-165, 2011</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in the regimen of studies included in this meta-analysis</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Caliskan, E., Dilbaz, S., Doger, E., Ozeren, S., Dilbaz, B., Erratum: Randomized comparison of 3 misoprostol protocols for abortion induction at 13-20 weeks of gestation (Journal of Reproductive Medicine (2005) 50 (173-180)), Journal of reproductive medicine for the obstetrician and gynecologist, 50, 732, 2005</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This article is an erratum for another excluded study (Caliskan 2005)</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Caliskan, E., Dilbaz, S., Doger, E., Ozeren, S., Dilbaz, B., Randomized comparison of 3 misoprostol protocols for abortion induction at 13-20 weeks of gestation, Journal of reproductive medicine for the obstetrician and gynecologist, 50, 173-180, 2005</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Caliskan, E., Doger, E., Cakiroglu, Y., Corakci, A., Yucesoy, I., Sublingual misoprostol 100 microgram versus 200 microgram for second trimester abortion: a randomised trial, European Journal of Contraception and Reproductive Health Care, 14, 55-60, 2009</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Carbonell, J. L., Torres, M. A., Reyes, R., Ortega, L., Garcia-Gallego, F., Sanchez, C., Second-trimester pregnancy termination with 600-mug vs. 400-mug vaginal misoprostol and systematic curettage postexpulsion: a randomized trial, Contraception, 77, 50-55, 2008</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cetin, C., Buyukkurt, S., Seydaoglu, G., Kahveci, B., Soysal, C., Ozgunen, F. T., Comparison of two misoprostol regimens for mid-trimester pregnancy terminations after FIGO’s misoprostol dosage recommendation in 2012, Journal of Maternal-Fetal & Neonatal MedicineJ Matern Fetal Neonatal Med, 29, 1314-7, 2016</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not a randomised controlled trial</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chaudhuri, S., Banerjee, P. K., Mundle, M., Mitra, S. N., A comparison of two regimens of misoprostol for second trimester medical termination of pregnancy: A randomized trial, Tropical doctor, 40, 144-148, 2010</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chen,Q.J., Zhang,J., Huang,Z.R., Fan,X.F., Wang,H.Y., Zhu,H., Hou,S.P., Liu,Y.H., Qiao,Q.Q., Zhang,P., Liu,Y., Qian,C.M., Tan,Y.D., Li,A.H., Meads,C., Zhang,W.H., Cheng,L.N., Mifepristone in combination with misoprostol for the termination of pregnancy at 8-16 weeks’ gestational age: A multicentre randomized controlled trial, Journal of Reproduction and Contraception, 24, 101-113, 2013</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mixed population of first and second trimester (period of gestation 8 to16 weeks), with a total of n=1112 of whom n=669 were the target population. Results for this subgroup could not be extracted.</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chen,Q.J., Hou,S.P., Meads,C., Huang,Y.M., Hong,Q.Q., Zhu,H.P., Cheng,L.N., Mifepristone in combination with prostaglandins for termination of 10-16 weeks gestation: A systematic review, European Journal of Obstetrics Gynecology and Reproductive Biology, 159, 247-254, 2011</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review with English and Chinese studies including comparison of different regimens of mifepristone with prostaglandins for abortion. Relevant studies are included individually in the current review.</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cheng, L, Termination of 10-16 weeks’ gestation with mifepristone plus misoprostol: a multicentre randomized clinical trial, Zhonghua fu chan ke za zhi, 34, 268-271, 1999</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Full text not written in English</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Crane, J. M., Young, D., Butt, K., Delaney, M., Hutchens, D., Carlan, S. J., Safety and efficacy of misoprostol orally and vaginally: A randomized trial [3], Obstetrics and gynecology, 98, 875-876, 2001</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Letter to Editor</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dalenda,C., Ines,N., Fathia,B., Malika,A., Bechir,Z., Ezzeddine,S., Hela,C., Badis,C.M., Two medical abortion regimens for late first-trimester termination of pregnancy: a prospective randomized trial, Contraception, 81, 323-327, 2010</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">First trimester abortion</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dickinson, J. E., Evans, S. F., A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality, Obstetrics and gynecology, 101, 1294-1299, 2003</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dickinson, J. E., Evans, S. F., The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination, American journal of obstetrics and gynecology, 186, 470-474, 2002</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ellis, S. C., Kapp, N., Vragpvoc, O., Borgata, L., Randomized trial of buccal versus vaginal misoprostol for induction of second trimester abortion, Contraception, 81, 441-445, 2010</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eslamian, L, Gosili, R, Jamal, A, Alyassin, A, A prospective randomized controlled trial of two regimens of vaginal misoprostol in second trimester termination of pregnancy, Acta medica iranica, 45, 497-500, 2007</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feldman, D. M., Borgida, A. F., Rodis, J. F., Leo, M. V., Campbell, W. A., A randomized comparison of two regimens of misoprostol for second-trimester pregnancy termination, American journal of obstetrics and gynecology, 189, 710-713, 2003</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gilbert, A., Reid, R., A randomised trial of oral versus vaginal administration of misoprostol for the purpose of mid-trimester termination of pregnancy, Australian and New Zealand Journal of Obstetrics and Gynaecology, 41, 407-410, 2001</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gomez Ponce de Leon, R., Wing, D. A., Misoprostol for termination of pregnancy with intrauterine fetal demise in the second and third trimester of pregnancy - a systematic review, Contraception, 79, 259-71, 2009</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review including second and third trimester abortion and regimen does not include mifepristone</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Guix, C, Palacio, M, Figueras, F, Bennasar, M, Zamora, L, Coll, O, Efficacy of two regimens of misoprostol for early second-trimester pregnancy termination, Fetal diagnosis and therapy, 20, 544-548, 2005</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Guo, Q., Qian, Z., Huang, L., Two cervical preparation regimens prior to surgical abortion at 10-14 weeks of gestation: A randomized clinical trial, Journal of Maternal-Fetal and Neonatal Medicine, 30, 2686-2689, 2017</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Heikinheimo, O., Suhonen, S., Haukkamaa, M., One- and 2-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy, Reproductive BioMedicine Online, 8, 236-9, 2004</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not a randomised controlled trial</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Herabutya,Y., Chanarachakul,B., Punyavachira,P., Induction of labor with vaginal misoprostol for second trimester termination of pregnancy in the scarred uterus, International Journal of Gynaecology and Obstetrics, 83, 293-297, 2003</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jain, J. K., Kuo, J., Mishell, D. R., Jr., A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination, Obstetrics and Gynecology, 93, 571-575, 1999</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jyothi, S, Pallavi, Mnv, Medical abortion by mifepristone with oral versus vaginal misoprostol, 56, 529-531, 2006</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Includes only first trimester pregnancies</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kapp,N., Borgatta,L., Stubblefield,P., Vragovic,O., Moreno,N., Mifepristone in second-trimester medical abortion: a randomized controlled trial, Obstetrics and Gynecology, 110, 1304-1310, 2007</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison of mifepristone versus digoxin</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Karsidag,A.Y.K., Buyukbayrak,E.E., Kars,B., Dansuk,R., Unal,O., Turan,M.C., Vaginal versus sublingual misoprostol for second-trimester pregnancy termination and effect on Doppler measurements, International Journal of Gynecology and Obstetrics, 106, 250-253, 2009</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Khazardoost, S., Hantoushzadeh, S., Madani, M. M., A randomised trial of two regimens of vaginal misoprostol to manage termination of pregnancy of up to 16 weeks, Australian and New Zealand Journal of Obstetrics and Gynaecology, 47, 226-229, 2007</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kurshid, R., Ahmed, A., Mir, S., Ul Shamas, I., To assess the efficacy of two regimens of misoprostol for second trimester pregnancy termination-a randomized comparison, Internet journal of gynecology and obstetrics, 14, 2010</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mahjabeen,, Khawaja, N. P., Rehman, R., Comparison of oral versus vaginal misoprostol for mid-trimester pregnancy termination, Jcpsp, Journal of the College of Physicians & Surgeons - Pakistan, 19, 359-62, 2009</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Milani, F., Sharami, S. H., Arjmandi, S., Comparison of sublingual and vaginal misoprostol for second-trimester pregnancy terminations, Journal of family and reproductive health, 8, 41-44, 2014</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nct,, A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion, <a href="https://clinicaltrials.gov/show/nct02708446" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Https:<wbr style="display:inline-block"></wbr>​//clinicaltrials<wbr style="display:inline-block"></wbr>​.gov/show/nct02708446</a>, 2016</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This is a clinical trial record, without details of the study</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nct,, Comparison of Two Regimens of Misoprostol for Second Trimester Medical Termination of Pregnancy, <a href="https://clinicaltrials.gov/show/nct00401440" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Https:<wbr style="display:inline-block"></wbr>​//clinicaltrials<wbr style="display:inline-block"></wbr>​.gov/show/nct00401440</a>, 2006</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This is a clinical trial record, without details of the study</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nct,, Misoprostol for Second Trimester Termination of Pregnancy, <a href="https://clinicaltrials.gov/show/nct00945997" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Https:<wbr style="display:inline-block"></wbr>​//clinicaltrials<wbr style="display:inline-block"></wbr>​.gov/show/nct00945997</a>, 2009</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This is a clinical trial record, without details of the study</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nigam, A., Singh, V. K., Prakash, A., Vaginal vs. oral misoprostol for mid-trimester abortion, International Journal of Gynecology and Obstetrics, 92, 270-271, 2006</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ozerkan, K., Ocakoglu, G., Rehimli, S., Uncu, G., Develioglu, O., A comparison of low-dose and high-dose protocols of vaginal misoprostol for second trimester termination of pregnancy, Clinical and Experimental Obstetrics and Gynecology, 36, 245-247, 2009</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rahimi-Sharbaf, F., Adabi, K., Valadan, M., Shirazi, M., Nekuie, S., Ghaffari, P., Khansari, N., The combination route versus sublingual and vaginal misoprostol for the termination of 13 to 24 week pregnancies: A randomized clinical trial, Taiwanese Journal of Obstetrics and Gynecology, 54, 660-665, 2015</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roy, G, Ferreira, E, Hudon, L, Marquette, G, The efficacy of oral versus vaginal misoprostol for second-trimester termination of pregnancy: a double-blind, randomized, placebo controlled trial, American journal of obstetrics and gynecology, 189, S70, 2003</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Saha,S., Bal,R., Ghosh,S., Krishnamurthy,P., Medical abortion in late second trimester - A comparative study with misoprostol through vaginal versus oral followed by vaginal route, Journal of the Indian Medical Association, 104, 81-84, 2006</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Shaheen, S., Khattak, N. N., Parveen, T., The use of vaginal misoprostol to terminate the pregnancy in second trimester, Medical Forum Monthly, 25, 20-2, 2014</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Shaw, K. A., Topp, N. J., Shaw, J. G., Blumenthal, P. D., Mifepristone-misoprostol dosing interval and effect on induction abortion times: a systematic review, Obstetrics & GynecologyObstet Gynecol, 121, 1335-47, 2013</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review including comparison of different regimens of mifepristone and misoprostol dosing interval. Relevant studies are included individually in the current review.</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tang, O. S., Lau, W. N., Chan, C. C., Ho, P. C., A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy, 111, 1001-5, 2004</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tang, O. S., Lee, S. W. H., Ho, P. C., A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone, Human Reproduction, 17, 2865-2868, 2002</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Includes pregnancies in first trimester only</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tanha, F. D., Golgachi, T., Niroomand, N., Ghajarzadeh, M., Nasr, R., Sublingual versus vaginal misoprostol for second trimester termination: A randomized clinical trial, Archives of Gynecology and Obstetrics, 287, 65-69, 2013</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Von Hertzen, H., Piaggio, G., Wojdyla, D., Huong, N. T. M., Marions, L., Okoev, G., Khomassuridze, A., Kereszturi, A., Mittal, S., Nair, R., Daver, R., Pretnar-Darovec, A., Dickson, K., Hinh, N. D., Bao, N. H., Tuyet, H. T. D., Peregoudov, A., Comparison of vaginal and sublingual misoprostol for second trimester abortion: Randomized controlled equivalence trial, Human Reproduction, 24, 106-112, 2009</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wang, Z, Zheng, Jq, Lin, Xh, Comparison of 3 methods of induction delivery for terminating midtrimester pregnancy of ulterus with scar, 17, 189-190, 2008</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Full text not written in English</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Webster, D., Penney, G. C., Templeton, A., A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol, British Journal of Obstetrics and Gynaecology, 103, 706-709, 1996</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Includes comparison of mifepristone doses, with similar misoprostol regimen for both groups.</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wong, K. S., Ngai, C. S. W., Yeo, E. L. K., Tang, L. C. H., Ho, P. C., A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: A randomized comparative trial, Human Reproduction, 15, 709-712, 2000</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr><tr><td headers="hd_h_ch10.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yazdani, S. H., Zeinalzadeh, M., Bouzari, Z., Golsorkhtabar-Amiri, M., Effects of vaginal versus oral misoprostol to terminate second-trimester pregnancy, Clinical and Experimental Obstetrics and Gynecology, 39, 529-531, 2012</td><td headers="hd_h_ch10.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mifepristone is not included in this regimen</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|